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Anyone can suffer a stroke at any time and the consequences of 
stroke are often severe. It therefore remains an important chal-
lenge to find new prognostic factors and to further evaluate the 
importance of known prognostic factors, as this may improve clini-
cal knowledge and management, and may guide new therapies. 
This thesis focusses on the influence of the prognostic factors tem-
perature and sex on treatment and outcome of patients with acute 
stroke. We aimed to assess the effect of body temperature manage-
ment on functional outcome in patients with acute stroke by per-
forming the Paracetamol (Acetaminophen) in Stroke 2 (PAIS 2) trial. 
In addition, we investigated sex differences in the acute manage-
ment of ischemic stroke and sex differences in long-term functional 
outcome after intracerebral hemorrhage.   
www.inger-deridder-phd.nl
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Chapter 1 
General introduction
General introduction
Temperature and sex as prognostic factors in stroke
Epidemiology and etiology of stroke
Anyone can suffer a stroke at any time and the consequences of stroke are often
severe. Annually, almost 40 000 people in the Netherlands,[1] and 15 000 000
people worldwide suffer new or recurrent stroke.[2] The burden of stroke is high,
with in the Netherlands an estimated 25 000 hospital admissions and 8 500 deaths
per year. Also, 240 000 people are living with the consequences of stroke.[1] As
the incidence of stroke rises with age, and as the population is aging, the burden
of stroke is expected to increase further, especially among women.[3]
In the Netherlands, 12 754 men and 11 246 women were admitted because of
stroke in 2012.[1] Mortality was higher in women: almost 2 000 more women died
of stroke in 2012 compared with men (5 222 vs 3 302).[1] Women seem to have
less favorable outcomes after stroke than men. For example, women have more
physical impairments and limitations in activities of daily living (ADL), as measured
by the Barthel index.[4, 5]
Strokes can be classified as ischemic stroke (IS) (87%), intracerebral hem-
orrhage (ICH) (10%) or subarachnoid hemorrhage (3%). The last is beyond the
scope of this thesis. Imaging of the brain can distinguish between these types.
Ischemic stroke is caused by a reduction of cerebral blood flow caused by occlusion
of a cerebral artery or arteriole. The causes of ischemic stroke are diverse, and
can be divided in large vessel disease, small vessel disease, cardioembolism
and other causes.[6] Intracerebral hemorrhage is caused by rupture of a cerebral
vessel. The most frequent risk factors are hypertension and amyloid angiopathy.[7]
Prognostic factors
Prognosis is a prediction of the course of a disease following its onset. It refers
to all possible outcomes and the frequency with which these outcomes occur.
Prognostic factors are characteristics that may be used to more accurately predict
outcome, may improve clinical knowledge and management and may guide new
therapies. Clinicians are often asked by patients or their family members to predict
outcome after stroke. Hence, it is important to determine reliable prognostic
factors. Comparing prognosis in patients with different characteristics may identify
prognostic factors. In statistical analyses of clinical trials prognostic factors are
important as they can act as confounders or effect modifiers. A confounder is a
variable that correlates with both the dependent and independent variable. An
effect modifier is a variable that modifies the effect of an intervention on outcome.
At the same time, prognostic factors are important in clinical trials because they
influence external validation and thereby determine to which patients the results of
the trial apply.[8] Considering the foregoing, it remains an important challenge to
find new prognostic factors and to further evaluate and explore the importance of
known prognostic factors.
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Sex as prognostic factor in stroke
Women differ from men in numerous ways, including differences in coagulation, im-
munity, hormone exposure, reproductive factors including pregnancy and childbirth,
and social factors.[27] Stroke risk factors also differ between women and men,
and may be unique for women, such as reproductive factors, or more common
in women, for instance atrial fibrillation and migraine. Women live longer and the
lifetime risk of stroke is therefore higher in women than in men (20% vs. 17%).[28]
Regarding social factors are women more likely to be living alone and widowed
before stroke, and have poorer prestroke functions and more comorbidities. A
multitude of studies found that women with IS have worse functional outcome
after stroke than men.[4, 5, 27, 29] However, due to a lack of consistency in the
selection of confounders in these studies, it is unclear whether this difference is
caused by their higher age, poorer prestroke functions and tendency to have more
severe strokes or whether other factors, like differences in stroke presentation,
acute management and effects of therapies, also play a role. As the burden of
stroke is higher in women than men, these are important issues to be addressed.
Results on mortality after ICH are conflicting. Women may have a higher mortality
or there may be no difference at all.[30, 31] A recent study showed no differences
in unfavorable outcome between women and men.[32]
Aims and outline of the thesis
The primary aim is of this thesis is to assess the effect of body temperature
management on functional outcome in patients with acute stroke. The secondary
aims are to investigate sex differences in the acute management of IS and sex
differences in long-term functional outcome after ICH.
Chapter 2 describes the rationale, background, design and results of the Parac-
etamol (Acetaminophen) in Stroke 2 (PAIS 2) trial, a multicenter, randomized,
double-blind, placebo-controlled clinical trial to assess the effect of high-dose
paracetamol in patients with acute stroke and a body temperature of 36.5°C or
above on functional outcome. In this chapter, I also describe the influence of base-
line body temperature on the effect of alteplase on functional outcome. Chapter
3 describes sex-related differences in long-term functional outcome after ICH. I
also describe differences between men and women in treatment with intravenous
alteplase and sex-related differences in the effect of intra-arterial treatment for
acute ischemic stroke. Chapter 4 and 5 provide a general discussion and summary
of the results presented in this thesis.
References
[1] Koopman, C. et al. Hart- en vaatziekten in Nederland 2014, cijfers over
kwaliteit van leven, ziekte en sterfte. Den Haag: Hartstichting, 2014.
[2] „Stroke: The global burden of stroke”. http://www.world-heart-federation.org/
cardiovascular-health/stroke/ (2016).
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Known prognostic factors in stroke
A wide variety of factors are known to predict outcome after stroke, with age and
stroke severity being the strongest. With age, chances of unfavorable functional
outcome and mortality increase.[9, 10] Older ischemic stroke patients have in-
creased change of dying or being discharged to nursing care facilities.[11] This
factor affects women the most, as women are on average 3 years older at stroke
onset than men (72 years compared with 69 years[1]). Stroke severity, measured
with the National Institutes of Health Stroke Scale (NIHSS), is also a strong predic-
tor of outcome. A higher score on the NIHSS is associated with a higher chance of
poor functional outcome.[12] Other prognostic factors are infarct volume[13] and
ICH volume,[14] intraventricular hemorrhage in case of ICH[15] and stroke etiology
in case of IS.[16] Comorbidities such as atrial fibrillation,[17] migraine, diabetes
mellitus[18] and dementia[19] may also play a role.
Temperature as prognostic factor in stroke
Subfebrile temperatures and fever are common in the first hours after stroke
onset. Within the first day after stroke onset, a third of the patients has a body
temperature higher than 37.5°C.[20] High body temperatures have been related to
poor functional outcome and death. A previous study has shown an early (within
24 hours after onset of symptoms) rise in body temperature was associated with
unfavorable outcome (aOR 1.30; 95% CI: 1.05 to 1.63) and death (aOR 1.51;
95% CI: 1.15 to 1.98).[21] Increased body temperature may either be a direct
effect of stroke or of concurrent infections. Several mechanisms may account
for the potential detrimental effect of high body temperature on clinical outcome.
Animal studies have suggested that a rise in temperature results in increased
ischemic damage through increased cerebral metabolic demands, increased blood-
brain barrier permeability, acidosis, and an increased release of excitatory amino
acids.[22] Vice versa, induced hypothermia reduced infarct volume and improved
functional outcome in animals.[23] Lowering body temperature and prevention of
fever are therefore likely candidates to improve functional outcome after stroke in
humans as well.
Paracetamol is one of the most commonly prescribed antipyretic drugs. Its
antipyretic properties are probably conferred by potent inhibition of prostaglandin
production in the central nervous system.[24] Moreover, paracetamol is well tol-
erated by patients with acute stroke and has virtually no side effects. In patients
admitted with acute ischemic stroke, it was shown to reduce body temperature by
about 0.3°C within 4 hours after treatment onset when prescribed at a daily dose of
six grams.[25] In the Paracetamol (Acetaminophen) in Stroke (PAIS) trial, patients
treated with paracetamol showed more improvement on the modified Rankin Scale
(mRS) at three-months than those treated with placebo, but this difference was
just not statistically significant (adjusted odds ratio (OR) 1.21; 95% CI: 0.97 to
1.51).[26] Based on these findings, we started the Paracetamol (Acetaminophen)
in Stroke 2 (PAIS 2) trial.
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Introduction
Subfebrile temperatures and fever are common in the first hours after stroke onset.
Within the first day after stroke onset, a third of the patients has a body temperature
higher than 37.5°C. High body temperatures have been related to poor functional
outcome and death.[1] In the Copenhagen study, the risk of poor outcome doubled
with every degree Celsius increase in body temperature measured within 12 hours
from stroke onset. In the Copenhagen study, the risk of poor outcome doubled
with every degree Celsius increase in body temperature measured within 12 hours
from stroke onset.[2] Increased body temperature may be either a direct effect
of stroke or of concurrent infections. Several mechanisms may account for the
potential detrimental effect of high body temperature on clinical outcome. Animal
studies have suggested that a rise in temperature results in increased ischemic
damage through increased cerebral metabolic demands, increased blood-brain
barrier permeability, acidosis, and an increased release of excitatory amino acids.[3]
Vice versa, induced hypothermia reduced infarct volume and improved functional
outcome in animals.[4] Lowering body temperature and prevention of fever are
therefore likely candidates to improve functional outcome after stroke in human
beings as well.
Based on observational studies, guidelines for the treatment of patients with
acute ischemic stroke[5, 6] or intracerebral hemorrhage[7, 8] advocate the use of
antipyretic drugs, such as paracetamol (acetaminophen) in a daily dose of 4 grams,
in patients with a body temperature higher than 37.5 or 38.0°C. However, routine
prescription of antipyretics may lead to unrecognized infections. Paracetamol is
one of the most commonly prescribed antipyretic drugs. Its antipyretic properties
are probably conferred by potent inhibition of prostaglandin production in the central
nervous system.[9] Moreover, paracetamol is well tolerated by patients with acute
stroke and has virtually no side effects in doses up to 6 grams daily, although in
patients with chronic liver failure this dose may lead to fatal complications.[10]
In patients admitted with acute ischemic stroke, it was shown to reduce body
temperature by about 0.3°C within 4 hours after treatment onset when prescribed
at a daily dose of 6 grams.[10]
In the first Paracetamol (Acetaminophen) in Stroke (PAIS) trial, a double blind,
placebo-controlled, randomized clinical trial of 1400 patients with acute stroke,
paracetamol reduced body temperature at 24 hours after start of treatment by
0.26°C (95% CI: 0.18-0.31). Patients treated with paracetamol showed more im-
provement on the modified Rankin Scale (mRS) at three months than those treated
with placebo, but this difference was not statistically significant (adjusted Odds
Ratio (aOR) 1.21; 95% Confidence Interval (CI): 0.97-1.51).[11] In the 661 patients
with a baseline body temperature between 37.0 and 39.0°C, paracetamol reduced
body temperature more effectively than in those with a baseline temperature lower
than 37.0°C (0.30°C vs. 0.19°C), increased the odds of improvement (OR 1.43;
95% CI: 1.02-1.97), and was associated with a 9% (95% CI: 1-16%; p=0.02) ab-
solute decrease in the risk of poor outcome, defined as a score on the mRS>2.
The relation between treatment with paracetamol and functional outcome was also
found in the 1080 patients with a body temperature of 36.5°C or higher (OR, 1.31;
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Abstract
Rationale
In the first hours after stroke onset, subfebrile temperatures and fever have been
associated with poor functional outcome. In the first Paracetamol (Acetaminophen)
in Stroke (PAIS) trial, a randomized clinical trial of 1400 patients with acute stroke,
patients who were treated with high-dose paracetamol showed more improvement
on the modified Rankin Scale (mRS) at 3 months than patients treated with placebo,
but this difference was not statistically significant. In the 661 patients with a baseline
body temperature of 37.0°C or above, treatment with paracetamol increased the
odds of functional improvement (odds ratio (OR) 1.43; 95% confidence interval (CI):
1.02-1.97). This relation was also found in the patients with a body temperature of
36.5 degrees Celsius or higher (OR 1.31; 95% CI 1.01-1.68). These findings need
confirmation.
Aim
To assess the effect of high-dose paracetamol in patients with acute stroke and a
body temperature of 36.5°C or above on functional outcome.
Design
The Paracetamol (Acetaminophen) In Stroke trial 2 (PAIS 2) is a multicenter, ran-
domized, double-blind, placebo-controlled clinical trial. We use a power of 85%
to detect a significant difference in the scores on the mRS of the paracetamol
group compared with the placebo group at a level of significance of 0.05 and
assume a treatment effect of 7%. Fifteen-hundred patients with acute ischemic
stroke or intracerebral hemorrhage and a body temperature of 36.5°C or above
will be included within 12 hours of symptom onset. Patients will be treated with
paracetamol in a daily dose of 6 g or matching placebo for three consecutive days.
PAIS 2 has been registered as NTR2365 in The Netherlands Trial Register.
Study outcomes
The primary outcome will be improvement on the mRS at 3 months as analyzed
by ordinal logistic regression.
Discussion
If high-dose paracetamol will be proven effective, a simple, safe, and extremely
cheap therapy will be available for many patients with acute stroke worldwide.
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Randomization
Patients are randomly allocated to paracetamol or an identical placebo. The study
drug is provided in white paper boxes, with unique ascending numbers. Treatment
allocation is based on a computer-generated list of random numbers with varying
block size, linked to a unique treatment number.
Blinding
An independent trial statistician (HL), who is otherwise not involved in the study, will
provide the list with allocated random numbers. The pharmacist of the coordinating
study center will have a confidential list that indicates the treatment allocation for
each randomized patient. Treatment assignment will be masked for all investi-
gators, study personnel, and patients. They will remain blinded to the treatment
assignments throughout the trial.
Intervention
Patients are treated with high-dose paracetamol (6 g daily) or matching placebo
started within 12 hours after the onset of symptoms and continued for 72 hours or
until discharge from hospital. The study medication (active compound or placebo)
will be administered through identical suppositories or tablets. The suppositories
may be used for patients with swallowing difficulties who do not have a nasogastric
tube yet. They will therefore predominantly be used in the first 24 hours after
admission, at the discretion of the treating physician and stroke nurse. To enhance
compliance in patients who do not suffer from swallowing difficulties and do not
need (continuation of) a nasogastric tube after the first 24 hours, treatment will
be continued with tablets up to 72 hours of treatment. In patients with persisting
swallowing deficits after the first 24 hours, tablets will be crushed and administered
via the nasogastric tube. In the first 3 days of enrollment, concurrent treatment
with open-label paracetamol is not allowed. For the treatment of pain, opioids are
recommended. If fever occurs during treatment with trial medication, the source of
fever should be ascertained and treated. If the treating physician thinks the fever
should also be treated with open-label paracetamol, the trial medication should be
stopped. The use of other antipyretic medication is allowed.
Study procedures
Before inclusion, the diagnosis of ischemic stroke or intracerebral hemorrhage
will be confirmed by CT or MRI. In case of clinical suspicion of liver disease, liver
enzymes will be measured and the patient will only be included if the lever enzymes
are lower than twice the upper limit of normal values. The randomization procedure
will be simple. Patients who meet the inclusion criteria and who have given written
informed consent are assigned a box containing the study medication. The box is
labeled with a unique study number. The local investigator will have to complete a
short web-based form to include the patient into the study. The anonymous patient
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95% CI 1.01-1.68). The large majority of these patients had a baseline temperature
between 36.5 and 37.5°C, and would not have received paracetamol according to
the above-mentioned guidelines.
Although the observed benefit of paracetamol in patients with temperatures
higher than 36.5°C is biologically plausible, this should be interpreted with caution,
as this concerns a subgroup analysis within a randomized clinical trial in which no
overall statistically significant beneficial effect could be demonstrated. Confirmation
of this observation in an independent study is therefore needed.[12] For this reason,
the aim of PAIS 2 is to assess the effect of high-dose paracetamol on functional
outcome in patients with acute stroke and body temperature of 36.5°C or above in
the first 12 hours after stroke onset.
Methods
Design
The Paracetamol (Acetaminophen) In Stroke 2 (PAIS 2) trial (Figure 2.1) is a
multicenter, randomized, double-blind, placebo-controlled clinical trial of high-dose
paracetamol.
PAIS 2
PARACETAMOL IN STROKE 2
Figure 2.1: The PAIS 2 trial logo.
Patients
Patients are eligible for inclusion if they have a diagnosis of ischemic stroke or
intracerebral hemorrhage and a body temperature of 36.5°C or higher. Other
inclusion and exclusion criteria are listed in Table 2.1.
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Secondary outcomes
Secondary outcome measures will include: poor outcome, defined as mRS>2
at three months; score on the Barthel index (BI), Telephone Interview for Cog-
nitive Status (TICS) score and Euroqol 5D (EQ5D) score at three months, body
temperature and markers of inflammation at 24 hours after start of treatment.
Data monitoring and safety committee
An independent data monitoring and safety committee (DMSC), consisting of two
experienced neurologists and clinical investigators and an independent statistician,
will meet at least annually. During the period of recruitment into the study, unblinded
but strictly confidential interim analyses of in-hospital mortality and of any other
information that is available on major outcome events, including serious adverse
events, will be supplied every year to the chairman of the DMSC, along with any
other analyses that the committee may request. In the light of these analyses, the
DMSC will advise the chairman of the steering committee about continuation of
the trial. These interim analyses will be prepared by the trial statistician, who is
unblinded. However, the trial statistician is otherwise not involved with the execution
of the trial as long as it runs.
Statistical analyses
Statistical analyses will be performed according to the intention-to-treat principle.
The primary effect estimate will be the common odds ratio of improvement on the
mRS assessed by means of multiple ordinal logistic regression, and be expressed
as an odds ratio with 95% confidence interval. In order to increase the power of the
study, adjustments will be made for chance imbalances between prognostic factors,
including stroke severity (NIHSS), stroke type, ischaemic stroke subtype (lacunar
versus non-lacunar), treatment with alteplase, previous stroke, atrial fibrillation,
and diabetes mellitus.
We will test for heterogeneity of treatment effect across important clinical sub-
groups of patients: stroke type (ischemic versus hemorrhagic stroke), severity
(dichotomized at the median NIHSS score), ischemic stroke subtype (lacunar ver-
sus non-lacunar ischemic stroke), time of onset of treatment (within 6 hours versus
between 6 and 12 hours after onset of symptoms), treatment with rtPA and body
temperature.[13, 14]
Sample size
The study will be powered to detect a statistically significant shift in the distribution
of the scores on the mRS at three months, assuming an effect that leads to a 7%
absolute increase in the cumulative proportion of patients with mRS between 0
and 2 in the paracetamol group, compared with patients on placebo. We base
the expected distribution of outcome categories on the placebo arm of the PAIS
trial.[11] Figure 2.3 shows the expected distributions of mRS categories. A total
study size of 1410 patients (2x705 pts) allows for a power (1-beta) of 85% to
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data will be automatically added to the study database. An automatically updated
log of the randomized patients will be available for each participating center.
Baseline data will include demographics, time of stroke onset, stroke severity
(measured by the National Institutes of Health Stroke Scale (NIHSS)), body tem-
perature at inclusion, pulse rate and blood pressure, results of CT scanning and
vascular history and vascular risk factors. In selected centers, a blood sample
will be taken on admission and 24 hours later, to assess markers of inflammation.
During hospital stay (serious) adverse events will be reported to the trial office.
Discharge data will include discharge destination, study compliance, body tem-
perature and blood pressure at 24 hours, laboratory findings at day 2-3, stroke
subtype and NIHSS at discharge. Follow-up will be carried out by the trial office
and will be conducted through telephone interviews. Outcome assessments will
be made through structured interviews by experienced research nurses of the
trial center who will be stationed at the trial office of the neurovascular division
of the department of neurology of the Erasmus MC University Medical Center
Rotterdam (Figure 2.2). Patient data will be entered through a web-based form.
Local investigators will be asked to fill out a one-page web-form at inclusion and
a one-page web-form at one week or at discharge. All data are stored in central
database, which is continuously updated.
Figure 2.2: Study design.
Primary outcomes
The primary outcome will be the shift on the score on the modified Rankin Scale at
three months. No dichotomization is necessary, as we will analyze shifts on the
whole scale.
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Discussion
Several observational studies have demonstrated a strong relationship between
increased body temperature in the first hours after symptom onset and poor func-
tional outcome after stroke.[1, 11] It remains unclear whether this relation is causal,
and more importantly, whether lowering of body temperature and prevention of
fever increases the likelihood of a favorable functional outcome. In the first PAIS
trial, treatment with paracetamol increased the odds of improvement at 3 months in
patients with a baseline body temperature between 37.0 and 39.0°C (OR 1.43; 95%
CI: 1.02-1.97) and was associated with a 9% (95% CI: 1-16%, p=0.02) absolute
decrease in the risk of unfavorable outcome. Because these findings are based on
subgroup analyses, confirmation is needed. We updated a Cochrane systematic
review of temperature-lowering therapy for acute ischemic stroke with the results of
PAIS.[16] The results of the review are now dominated by the results of this study,
and the estimate of the treatment effect leaves room for a substantial reduction in
poor outcome (OR 0.93; 95% CI: 0.57-1.50). It should be noted however, that this
systematic review combined physical and pharmacological strategies to reduce
body temperature and included several phase 2 studies that had a long time window
after symptom onset for the start of treatment. The last issue is crucial because
the association of body temperature with clinical outcome is likely limited to the first
12-24 hours of stroke onset, and the amount of salvageable brain tissue will rapidly
diminish over time.[1] We have previously shown that paracetamol reduces body
temperature in patients with acute stroke within 4 hours after start of treatment.[17]
It seems therefore rational to include patients up to 12 hours after onset of stroke
symptoms.
Whether increased body temperature in acute stroke contributes to poor out-
come or is just a marker of severe stroke remains unclear. Hyperthermia has been
suggested to be an epiphenomenon of the extent of cerebral damage. Animal
studies suggest that hyperthermia is associated with larger infarct size.[18] Body
temperature may also be increased because of stroke-associated infections and
central dysregulation.
Increased body temperature may also be an indicator of local cerebral inflam-
mation and neuronal tissue injury. Cyclo-oxygenase-2 (COX-2) isoenzymes play
an important role in temperature regulation at the level of the hypothalamus.[19] In
animal studies, COX-2 mRNA and protein are upregulated 12 to 24 hours after the
onset of focal cerebral ischemia.[20] COX-2 is expressed in neurons and vascular
cells at the border of the ischemic territory.[21] COX-2 has also been found in the
human brain after stroke.[22] COX-2 inhibition reduces neuronal damage in animal
models of focal and global cerebral ischemia.[23] These observations raise the pos-
sibility that COX-2 reaction products, such as prostaglandin 2 (PGE2), contribute
to cerebral ischemic injury, either directly, or through temperature elevation. It has
been shown that paracetamol is effective in blocking cerebral COX-2 and lowering
cerebral PGE2 production.[24] This indicates the possibility of a direct neuroprotec-
tive effect of paracetamol in case of ischemic stroke. Early after ICH also a strong
pro-inflammatory response has been observed. Therefore, our hypothesis is that
lowering cerebral COX-2 also has a neuro-protective effect in ICH.
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detect a significant difference in the scores on the mRS of the paracetamol group
compared with the placebo group at a level of significance of 0.05.[15] The total
study size that will be needed is rounded to 1500 patients.
Figure 2.3: Distribution of scores on the modified Rankin Scale in the placebo group
(mRS_C) based on data from PAIS (11) and estimated distribution of modified
Rankin Scale scores in the intervention group (mRS_I) based on the assumption
of a 7% shift in the cumulative probability of mRS 0-2.
Study organization and funding
PAIS 2 is an independent academic trial. This study is run by an executive com-
mittee that consists of members of the steering committee (SC) who are actually
involved in carrying out the study on a daily basis (Table 2.2). The recruitment
period will be 4.5 years. The central coordination is performed by the SC. They
will meet at least once a year, and monitor the progress of the study. Decisions
regarding continuation of the trial, amendments to the protocol, and publication
of its results (taking into account the advice of the DMSC) will be taken by the
SC. The SC strives for consensus decisions, but may have to settle for majority
votes. The trial is funded by the Stichting Neurovasculair Onderzoek Rotterdam
(Foundation for Neurovascular Research Rotterdam); additional support has been
requested.
Public disclosure and publication policy
The investigators aim at public disclosure and publication of the research data
in highly-ranked, international peer-reviewed, scientific journals. Results of this
research project will be disclosed unreservedly. All authors will have to comply
with the Vancouver protocol for authorship.
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Table 2.1: Inclusion- and exclusion criteria.
Inclusion criteria
• a clinical diagnosis of ischemic stroke or intracerebral hemorrhage, con-
firmed by CT or MRI scan
• a measurable deficit on the National Institutes of Health Stroke Scale
(NIHSS)
• the possibility to start treatment within 12 hours of symptom onset (for
patients who noticed symptoms when awaking from sleep, the time last
seen well is taken as the time of onset of symptoms
• body temperature of 36.5°C or higher
• age of 18 years or older
• signed informed consent
Exclusion criteria
• history of liver disease or alcohol abuse
• liver enzymes (ASAT, ALAT, AP or gamma-GT) increased above twice the
upper limit of normal values
• allergy to paracetamol
• death appearing imminent at the time of inclusion
• any pre-stroke impairment that has led to dependency (modified Rankin
Scale (mRS)>2) and therefore interferes with the assessment of functional
outcome
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With the PAIS trial, we showed that a large phase III trial with high-dose parac-
etamol is feasible in The Netherlands, although the recruitment rate was lower than
expected. Fourteen hundred patients were included instead of the 2500 patients
that were aimed for. Lessons learned from successful participating study centers in
the PAIS trial were in particular that inclusion of patients has to be made as simple
as possible. The PAIS 2 trial will therefore use a simple web-based randomization
and data entry procedure. In addition, to enhance compliance, suppositories will
be made available for rectal administration for the first 24 hours, after which time
paracetamol will be administered orally. With oral administration, peak plasma
levels are reached after 30 minutes to 1 hour; with rectal administration after 1
hour. Differences in pharmacokinetics between oral and rectal administration are
therefore negligible. If oral administration is applied whenever possible, this reflects
daily clinical practice best. This is the most important reason why intravenous
administration of paracetamol has not been considered in this trial. In addition,
intravenous administration is much more expensive and peak plasma levels are
reached just slightly earlier (10-20 minutes after administration) when compared
with oral administration.
We use ordinal logistic regression to estimate a treatment effect on the modified
Rankin Scale. A common odds ratio for improvement on the scale will be estimated.
Simulation studies have indicated that ordinal logistic regression is a more powerful
method for analysis of trials with ordered categorical outcome data when compared
with the more commonly used sliding dichotomy approach, and have proven its
robustness against violations of the proportional odds assumption.[25]
The PAIS trial also showed that treatment with high-dose paracetamol is safe.
The number of adverse events was similar in the treatment and placebo groups.
We will closely monitor the adherence to inclusion and exclusion criteria in order to
prevent inclusion of patients at increased risk of liver failure.
In conclusion, PAIS 2 will be a simple but highly relevant clinical trial. The
treatment strategy tested is safe and inexpensive. If high-dose paracetamol will be
proven beneficial, a simple, safe, and extremely cheap therapy will be available for
many patients with acute stroke worldwide.
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Chapter 2.2 
Paracetamol (Acetaminophen) 
in Stroke 2 (PAIS 2): Results of 
a randomized, double-blind 
placebo-controlled clinical trial 
Temperature as prognostic factor in stroke
Background
High body temperatures after stroke are associated with unfavorable outcome.[1]
The risk of poor outcome doubles with every degree Celsius increase in body
temperature measured within the first 12 h from stroke onset.[2]
Animal studies have shown that high body temperature results in increased
ischemic damage through increased cerebral metabolic demands, damage of
the blood–brain barrier, acidosis, and an increased release of excitatory amino
acids.[3] Lowering body temperature and prevention of fever are therefore simple
and promising approaches to improve functional outcome after stroke.
There is currently no evidence that strategies to prevent or treat high body
temperature reduce case fatality and improve functional outcome after stroke. US
stroke guidelines recommend the use of antipyretic drugs when body temperature
exceeds 38.0°C.[4] European (ESO) guidelines do not make any recommendation
for treating hyperthermia as a means to improve outcome in patients with ischemic
stroke (IS) and recommend further research.[5] A possible concern with routine
prescription of antipyretic drugs is that this may delay the diagnosis of an infection.
Paracetamol is one of the most commonly prescribed antipyretic drugs. It
blocks cerebral COX-2 and lowers cerebral PGE2 production.[6] In patients with
acute stroke, treatment with high-dose paracetamol reduces body temperature
about 0.3°C within 4 hours after start of treatment.[7] A post-hoc analysis of the
Paracetamol (Acetaminophen) in Stroke (PAIS) trial suggested that treatment
with high-dose paracetamol within 12 hours after stroke onset might improve
functional outcome in patients with a body temperature of 36.5°C or higher (OR
1.31; 95% CI: 1.01–1.97).[8, 9] The large majority of these patients (n=1.022 (73%))
had a baseline temperature between 36.5°C and 38.0°C, and would not have
received paracetamol according to the aforementioned guidelines. Although the
observed benefit of paracetamol in patients with temperatures higher than 36.5°C
is biologically plausible, this should be interpreted with caution, as this concerns a
subgroup analysis within a randomized clinical trial in which no overall statistically
significant beneficit could be demonstrated. Confirmation of this observation in
an independent study is therefore needed.[10] Hence, the aim of PAIS 2 was to
assess the effect of high-dose paracetamol on functional outcome in patients with
acute stroke and a body temperature of 36.5°C and higher in the first 12 hours
after stroke onset.
Methods
Study design and randomization
PAIS 2 was a multicenter, randomized, double-blind, placebo-controlled clinical
trial. The study protocol has been published previously.[8] In short, patients were
randomly allocated to treatment with high-dose paracetamol (intervention group) or
placebo (control group) in a 1:1 allocation ratio. Treatment allocation was based on
a computer-generated list of random numbers with varying block size, linked to a
unique treatment number. The list was provided by the independent trial statistician.
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Abstract
Background
Subfebrile body temperature and fever in the first days after stroke are strongly
associated with unfavorable outcome. A sub-group analysis of a previous trial
suggested that early treatment with paracetamol may improve functional outcome
in patients with acute stroke and a body temperature of 36.5°C or higher. In the
present trial, we aimed to confirm this finding.
Methods
PAIS 2 was a multicenter, randomized, double-blind, placebo-controlled clinical
trial. We aimed to include 1500 patients with acute ischemic stroke or intracerebral
hemorrhage within 12 hours of symptom onset. Patients were treated with parac-
etamol in a daily dose of 6 g or matching placebo for 3 consecutive days. The
primary outcome was functional outcome at 3 months, assessed with the modified
Rankin Scale (mRS) and analyzed with multivariable ordinal logistic regression.
Due to slow recruitment and lack of funding the study was stopped prematurely.
Results
Between December 2011 and October 2015, we included 256 patients, of whom
136 (53%) were allocated to paracetamol. In this small sample, paracetamol had
no effect on functional outcome (acOR 1.15; 95% CI: 0.74-1.79). There was no dif-
ference in the number of serious adverse events (paracetamol n=35 (26%) versus
placebo n=28 (24%)).
Conclusion
Treatment with high-dose paracetamol appeared safe. The effect of high-dose
paracetamol on functional outcome remains uncertain. Therefore, a very large trial
of early treatment with high dose paracetamol is still needed.
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Analysis 
Follow-Up 
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Figure 2.4: CONSORT 2010 Flow Diagram.
Local investigators enrolled the patients and patients were assigned a box, labeled
with a unique study number, containing study medication. Treatment allocation
was masked for everyone except the trial statistician, throughout the trial. The
study was approved by a central research ethics committee and the research board
of each of the 11 participating centers. All patients or their legal representatives
provided written informed consent. The trial was registered in the Netherlands Trial
Register (NTR2365) and funded by the Foundation for Neurovascular Research
Rotterdam.
Patients
Patients were eligible for inclusion if they had a diagnosis of ischemic stroke (IS) or
intracerebral hemorrhage (ICH), a body temperature of 36.5°C or higher, were 18
years or older, and could be treated within 12 hours after stroke onset. Exclusion
criteria were a history of liver disease or alcohol abuse, allergy to paracetamol,
liver enzymes (ASAT, ALAT, AP, or gamma-GT) increased above twice the upper
limit of normal values, death appearing imminent at the time of inclusion, and any
pre-stroke impairment that has led to dependency (modified Rankin Scale > 2) and
therefore interfering with the assessment of functional outcome.
Procedures
Before inclusion, the diagnosis of ischemic stroke or ICH was confirmed by com-
puted tomography (CT) or magnetic resonance imaging (MRI). Patients were
treated with high-dose paracetamol (6 g daily) or matching placebo, started within
12 hours after onset of symptoms and continued for 72 hours or until discharge
from hospital if earlier. The study medication (active compound and placebo)
was administered through identical tablets or suppositories. In the first 3 days of
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enrollment, concurrent treatment with open-label paracetamol was not allowed.
The use of other antipyretic medication was allowed. Baseline characteristics were
collected, and at 3 months outcome scores and (serious) adverse events, including
infections, were assessed by telephone interview by experienced research nurses
of the trial office of the neurovascular division of the Erasmus MCUniversity Medical
Center Rotterdam. For more details, we refer to the study protocol.[8]
Outcome
The primary outcome was the shift on the modified Rankin scale (mRS) score at
90 days.[11] Secondary outcomes were body temperature at 24 hours after start of
treatment, unfavorable outcome at 90 days, defined as a score on the mRS of 3 or
more, activities of daily life, measured with the Barthel Index (BI)[12] and quality of
life, measured with the EuroQol 5D 3L score at 90 days, estimated with the Dutch
tariff.[13]
Sample size
We assumed an effect of paracetamol that leads to a 7% absolute increase in the
cumulative proportion of patients with mRS between 0 and 2 in the paracetamol
group, compared with placebo. We used a power (1-beta) of 0.85 to detect a
significant difference in the scores on the mRS of the paracetamol group compared
with the placebo group at a level of significance of 0.05. The total study size needed
was calculated and rounded to 1500 patients.
Statistical analysis
Statistical analyses were performed according to the intention-to-treat principle.
The primary effect estimate was the common Odds Ratio (cOR) of improvement
on the mRS score assessed by means of multiple ordinal logistic regression
analysis. A cOR larger than 1 would indicate a positive effect of treatment, with
shift towards better functional outcome. Adjustments were made for age, NIHSS
at admission and stroke type. For the continuous variables EuroQol 5D 3L and
body temperature difference we used linear regression analysis. We tested for
heterogeneity of treatment effect across important clinical subgroups of patients, as
defined in the study protocol.[8] We also performed a systemic review of literature
and updated a previous meta-analysis of paracetamol in acute stroke, both for all
patients and for patients with a body temperature of 36.5°C or above (when data
available).[14] Data were added to the meta-analysis at individual patient level.
Favorable outcome in this meta-analysis was defined as an mRS 0-2. The effect
estimate was Odds Ratio, with an OR larger than 1 indicating a positive effect of
treatment. All analyses were performed with STATA 14 (StataCorp. 2015. Stata
Statistical Software: Release 14. College Station, TX: StataCorp LP.)
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Unknown 52 (41%) 40 (37%)
Treatment characteristics
Treatment with rt-PA 63 (47%) 53 (45%)
Time from onset to randomization,
minutes (median, IQR)
363 (243-570) 390 (270-600)
Treatment with study medication within 6
hours after onset of symptoms
68 (50%) 63 (53%)
SD=standard deviation; mRS=modified Rankin Scale; IQR=interquartile range;
NIHSS=National Institutes of Health Stroke Scale, CRP=C-reactive protein,
rt-PA=recombinant tissue plasma activator.
*Based on definitions of the Trial of ORG10172 in Acute Stroke Therapy (TOAST) criteria.
Clinical outcomes
We found no difference in improvement on the mRS score between patients treated
with paracetamol and those treated with placebo (cOR 1.02; 95% CI: 0.66 to 1.58)
(Figure 2.5). Adjustment for age, NIHSS at admission and stroke type had no
appreciable effect (acOR 1.15; (95% CI: 0.74 to 1.79). The treatment had no effect
on secondary outcome measures (Table 2.4) except for body temperature at 24
hours, which was significantly lower in paracetamol-treated patients compared
with control patients (median body temperature at 24 hours in paracetamol treated
patients 36.8°C vs 37.0°C in placebo treated patients, mean temperature difference
-0.27°C; 95% CI -0.44 to -0.11°C). We did not find a statistically significant effect of
paracetamol on functional outcome in any pre-specified subgroup (Figure 2.6).
Safety outcomes
Mortality at 3 months did not differ between the paracetamol and placebo groups
(n=11 (8%) vs. n=15 (13%) respectively). There were no cases of liver failure, and
the rate of infections was similar in both groups (Table 2.5).
Meta-analysis
The overall OR in the meta-analysis of all controlled trials with paracetamol after
acute stroke did not indicate a difference between paracetamol and placebo (OR
1.04; 95% CI: 0.87 to 1.25)(Figure 2.7). Figure 2.8 shows the meta-analysis of
data from patients with a baseline temperature of 36.5°C and higher, with similar
results (overall OR 1.08; 95% CI: 0.88-1.33).
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Results
Baseline characteristics
Recruitment started in December 2011 and inclusion was halted on October, 1st
2014 because of slow recruitment and lack of funding. The trial ended on January,
1st 2015. In total, 256 patients were randomized, of whom 136 (53%) were allocated
to paracetamol (Figure 2.4). Two patients withdrew informed consent. Mean age
was 69 years in both groups. Baseline characteristics did not differ between the
treatment groups, except for sex (paracetamol 50% men; placebo 64% men) (Table
2.3). Two patients (0.4%) were lost to follow-up.
Table 2.3: Baseline characteristics by treatment allocation.
Paracetamol
(n=136)
Placebo
(n=118)
Medical history
Age, years (mean, SD) 69 (14) 69 (13)
Male sex 68 (50%) 76 (64%)
Hypertension 78 (57%) 65 (55%)
Atrial fibrillation 15 (11%) 17 (14%)
Diabetes mellitus 20 (15%) 20 (17%)
Previous stroke 33 (24%) 22 (19%)
Smoking 61 (45%) 55 (47%)
Pre mRS score (median, IQR) 0 (0 -0) 0 (0 -0)
Physical examination
NIHSS at admission (median, IQR) 6 (3-8) 5 (2-8)
Systolic blood pressure at admission,
mmHg (median, IQR)
154 (140-170) 160 (144-170)
Diastolic blood pressure at admission,
mmHg (median, IQR)
81 (70-90) 82 (70-90)
Heart rate at admission, beats/min
(median, IQR)
79 (69-89) 79 (70-89)
Body temperature at admission, °C
(median, IQR)
36.9 (36.7-37.2) 36.8 (36.6-37.2)
CRP at admission, mg/L (median, IQR) 3 (1-8) 3 (1-7)
Stroke type
Ischemic stroke 127 (93%) 107 (91%)
Ischemic stroke subtype*
Large vessel disease 22 (17%) 19 (18%)
Cardiac embolism 21 (17%) 16 (15%)
Small vessel disease 26 (20%) 21 (20%)
Other 6 (5%) 11 (10%)
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Recruitment started in December 2011 and inclusion was halted on October, 1st
2014 because of slow recruitment and lack of funding. The trial ended on January,
1st 2015. In total, 256 patients were randomized, of whom 136 (53%) were allocated
to paracetamol (Figure 2.4). Two patients withdrew informed consent. Mean age
was 69 years in both groups. Baseline characteristics did not differ between the
treatment groups, except for sex (paracetamol 50% men; placebo 64% men) (Table
2.3). Two patients (0.4%) were lost to follow-up.
Table 2.3: Baseline characteristics by treatment allocation.
Paracetamol
(n=136)
Placebo
(n=118)
Medical history
Age, years (mean, SD) 69 (14) 69 (13)
Male sex 68 (50%) 76 (64%)
Hypertension 78 (57%) 65 (55%)
Atrial fibrillation 15 (11%) 17 (14%)
Diabetes mellitus 20 (15%) 20 (17%)
Previous stroke 33 (24%) 22 (19%)
Smoking 61 (45%) 55 (47%)
Pre mRS score (median, IQR) 0 (0 -0) 0 (0 -0)
Physical examination
NIHSS at admission (median, IQR) 6 (3-8) 5 (2-8)
Systolic blood pressure at admission,
mmHg (median, IQR)
154 (140-170) 160 (144-170)
Diastolic blood pressure at admission,
mmHg (median, IQR)
81 (70-90) 82 (70-90)
Heart rate at admission, beats/min
(median, IQR)
79 (69-89) 79 (70-89)
Body temperature at admission, °C
(median, IQR)
36.9 (36.7-37.2) 36.8 (36.6-37.2)
CRP at admission, mg/L (median, IQR) 3 (1-8) 3 (1-7)
Stroke type
Ischemic stroke 127 (93%) 107 (91%)
Ischemic stroke subtype*
Large vessel disease 22 (17%) 19 (18%)
Cardiac embolism 21 (17%) 16 (15%)
Small vessel disease 26 (20%) 21 (20%)
Other 6 (5%) 11 (10%)
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Figure 2.5: Effect of the intervention on primary outcome.
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
aOR, 95% CI
Favors paracetamol
Stroke type
p=0.51Ischemic stroke (n=232)
Intracerebral hemorrhage (n=20)
Stroke severity
p=0.29NIHSS < 6 (n=135)
NIHSS ≥ 6 (n=117) 
Time to treatment
p=0.80
> 6 h (n=129)
Baseline body temperature
p=0.1536.5 to 37.0°C (n=165)
> 37.0°C (n=87)
Treatment with alteplase
p=0.83Yes (n=116)
No (n=133)
p for interaction
Favors placebo
≤ 6 h (n=123)
All patients (n=252)
Figure 2.6: Subgroup Analysis. Adjusted Odds Ratio (aOR; black dots), 95%
Confidence Interval (CI; horizontal lines), P values for the interaction between the
treatment effect and any subgroup variable.
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Figure 2.5: Effect of the intervention on primary outcome.
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p=0.51Ischemic stroke (n=232)
Intracerebral hemorrhage (n=20)
Stroke severity
p=0.29NIHSS < 6 (n=135)
NIHSS ≥ 6 (n=117) 
Time to treatment
p=0.80
> 6 h (n=129)
Baseline body temperature
p=0.1536.5 to 37.0°C (n=165)
> 37.0°C (n=87)
Treatment with alteplase
p=0.83Yes (n=116)
No (n=133)
p for interaction
Favors placebo
≤ 6 h (n=123)
All patients (n=252)
Figure 2.6: Subgroup Analysis. Adjusted Odds Ratio (aOR; black dots), 95%
Confidence Interval (CI; horizontal lines), P values for the interaction between the
treatment effect and any subgroup variable.
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Figure 2.7: Updated meta-analysis of all studies with paracetamol after acute
stroke in all patients. Favorable outcome is defined as an mRS 0-2. An OR larger
than 1 indicates a positive effect of treatment.
References figure 2.7
1. Dippel DW, van Breda EJ, van Gemert HM, van der Worp HB, Meijer RJ,
Kappelle LJ, et al. Effect of paracetamol (acetaminophen) on body temperature in
acute ischemic stroke: A double-blind, randomized phase ii clinical trial. Stroke.
2001;32:1607-1612
2. Koennecke HC, Leistner S. Prophylactic antipyretic treatment with ac-
etaminophen in acute ischemic stroke: A pilot study. Neurology. 2001;57:2301-
2303
3. Kasner SE, Wein T, Piriyawat P, Villar-Cordova CE, Chalela JA, Krieger DW, et
al. Acetaminophen for altering body temperature in acute stroke: A randomized
clinical trial. Stroke. 2002;33:130-134
4. Dippel DW, van Breda EJ, van der Worp HB, van Gemert HM, Meijer RJ,
Kappelle LJ, et al. Effect of paracetamol (acetaminophen) and ibuprofen on body
temperature in acute ischemic stroke pisa, a phase ii double-blind, randomized,
placebo-controlled trial [isrctn98608690]. BMC Cardiovasc Disord. 2003;3:2
5. den Hertog HM, van der Worp HB, van Gemert HM, Algra A, Kappelle LJ, van
Gijn J, et al. The paracetamol (acetaminophen) in stroke (pais) trial: A multicentre,
randomised, placebo-controlled, phase iii trial. Lancet Neurol. 2009;8:434-440
6. This manuscript.
45
Chapter 2
Table 2.5: Safety outcomes.
Paracetamol (n=135) Placebo (n=117)
Safety variables
Death within 7 days 5 (4%) 7 (6%)
Death within 90 days 11 (8%) 15 (13%)
Serious adverse events
Any serious adverse event 35 (26%) 28 (24%)
Pneumonia 4 (3%) 3 (3%)
Urinary tract infection 3 (2%) 3 (2%)
Other infection 0 (0%) 1 (1%)
Liver failure 0 (0%) 0 (0%)
Gastro-intestinal hemorrhage 1 (1%) 0 (0%)
Discussion
In this prematurely terminated, small trial in patients with acute stroke and a body
temperature of 36.5°C and higher, we found that treatment with high-dose parac-
etamol was safe, but did not improve functional outcome at 3 months. Treatment
with paracetamol lowered body temperature by 0.3°C. Therapeutic hypothermia
has been accepted as an effective treatment after cardiac arrest[15] and in hypoxic-
ischemic encephalopathy in neonates.[16] An important issue in the ongoing dis-
cussion on cardiac arrest is the optimal target temperature. A recent study showed
that a target temperature of 36.0°C may be non-inferior to therapeutic hypothermia
aiming at a body temperature of 33.0-34.0°C.[17] In that study, patients who were
maintained at a target of 36.0°C seemed to have less serious side effects, including
hypokalemia, pneumonia and bleeding complications, but these differences were
not statistically significant, except for hypokalemia (p=0.02).[17] Other subjects of
debate are time to initiation of hypothermia, time to achieve target temperature,
treatment duration and rewarming methods.[18] These issues are also applicable
to therapeutic hypothermia in acute stroke.[19]
Whereas clinical studies assessing the effect of therapeutic hypothermia on
outcome after acute stroke have so far been too small to demonstrate a benefit,
pharmacological treatment aimed at maintaining normothermia may be an alterna-
tive. Six studies have been performed on pharmacological hypothermia in acute
stroke. Five of these studies used paracetamol as antipyretic drug.[14] These
studies, except for PAIS, were small and designed to test safety and feasibility.
They showed no effect on outcome. In PAIS, more patients in the paracetamol
group than in the placebo group improved beyond expectation, but this effect
was just not statistically significant (aOR 1.20; 95% CI: 0.96–1.50). In a post-hoc
analysis of a subgroup of patients with a body temperature of 37.0°C or above,
treatment with paracetamol was associated with improved outcome. A previous
meta-analysis using a dichotomized outcome showed a trend towards a favorable
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Figure 2.7: Updated meta-analysis of all studies with paracetamol after acute
stroke in all patients. Favorable outcome is defined as an mRS 0-2. An OR larger
than 1 indicates a positive effect of treatment.
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Table 2.5: Safety outcomes.
Paracetamol (n=135) Placebo (n=117)
Safety variables
Death within 7 days 5 (4%) 7 (6%)
Death within 90 days 11 (8%) 15 (13%)
Serious adverse events
Any serious adverse event 35 (26%) 28 (24%)
Pneumonia 4 (3%) 3 (3%)
Urinary tract infection 3 (2%) 3 (2%)
Other infection 0 (0%) 1 (1%)
Liver failure 0 (0%) 0 (0%)
Gastro-intestinal hemorrhage 1 (1%) 0 (0%)
Discussion
In this prematurely terminated, small trial in patients with acute stroke and a body
temperature of 36.5°C and higher, we found that treatment with high-dose parac-
etamol was safe, but did not improve functional outcome at 3 months. Treatment
with paracetamol lowered body temperature by 0.3°C. Therapeutic hypothermia
has been accepted as an effective treatment after cardiac arrest[15] and in hypoxic-
ischemic encephalopathy in neonates.[16] An important issue in the ongoing dis-
cussion on cardiac arrest is the optimal target temperature. A recent study showed
that a target temperature of 36.0°C may be non-inferior to therapeutic hypothermia
aiming at a body temperature of 33.0-34.0°C.[17] In that study, patients who were
maintained at a target of 36.0°C seemed to have less serious side effects, including
hypokalemia, pneumonia and bleeding complications, but these differences were
not statistically significant, except for hypokalemia (p=0.02).[17] Other subjects of
debate are time to initiation of hypothermia, time to achieve target temperature,
treatment duration and rewarming methods.[18] These issues are also applicable
to therapeutic hypothermia in acute stroke.[19]
Whereas clinical studies assessing the effect of therapeutic hypothermia on
outcome after acute stroke have so far been too small to demonstrate a benefit,
pharmacological treatment aimed at maintaining normothermia may be an alterna-
tive. Six studies have been performed on pharmacological hypothermia in acute
stroke. Five of these studies used paracetamol as antipyretic drug.[14] These
studies, except for PAIS, were small and designed to test safety and feasibility.
They showed no effect on outcome. In PAIS, more patients in the paracetamol
group than in the placebo group improved beyond expectation, but this effect
was just not statistically significant (aOR 1.20; 95% CI: 0.96–1.50). In a post-hoc
analysis of a subgroup of patients with a body temperature of 37.0°C or above,
treatment with paracetamol was associated with improved outcome. A previous
meta-analysis using a dichotomized outcome showed a trend towards a favorable
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effect of temperature-lowering treatment.[14] Furthermore, the QASC trial showed
that early detection and management of fever (body temperature > 37.5°C), swal-
lowing difficulties and hyperglycaemia led to a significantly higher chance of being
alive or independent during follow up.[20] This trial was however not designed to
determine which of these interventions made the difference.
The results of PAIS 2 are neutral. However, because of serious lack of power
we cannot exclude an alternative result. We updated the previous meta-analysis
with the results of PAIS 2 (Figure 2.7) and found no significant difference between
temperature-lowering treatment and control in the proportion of patients who were
alive and independent (mRS2)(overall OR 1.04; 95% CI: 0.87 to 1.25). We also
performed a meta-analysis of data of all patients with a baseline temperature of
36.5°C or above (Figure 2.8), which showed comparable results (overall OR 1.08;
95% CI: 0.88-1.33). However, these analyses were binary and did not have the
advantage of ordinal regression analysis.
The main limitation of this study is that it was preliminary stopped and therefore
the study is strongly underpowered to detect a difference in functional outcome
after treatment with high-dose paracetamol in acute stroke. Patient recruitment was
low, which was most likely caused by the low intensity of trial coordination activities,
such as creating awareness for the study, providing information, feedback and
support to the participating centers. This was a consequence of the low budget.
The simultaneous conduct of several large randomized clinical trials of acute stroke
treatment in the Netherlands also added to the low recuitment rate. A strength of
the study is that it allowed us to update the meta-analysis with the results of this
study.
The results of PAIS 2 provide no evidence for the routine use of high dose
paracetamol in acute stroke. Although the relative effect may be low, an absolute
risk reduction in unfavorable outcome of 5% may be clinically relevant, considering
the large number of patients involved and the simple, safe, and cheap nature of
the therapy. Taking into account the results of the updated meta-analysis, such a
moderate effect could not be excluded. Further large clinical trials are necessary
to further explore this finding. This will be assessed in the trial PRECIOUS trial:
Prevention of Complications to Improve Outcome in elderly patients with Stroke
(www.precious-trial.eu).
Conclusion
Treatment with paracetamol after acute stroke appears safe. However, the effect
of treatment with high-dose paracetamol after acute stroke remains unclear. A
very large trial of early treatment with paracetamol after acute stroke is needed to
answer this question.
References
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Figure 2.8: Updated meta-analysis of all studies with paracetamol after acute
stroke in patients with a body temperature of 36.5 degrees and higher. Favorable
outcome is defined as an mRS 0-2. An OR larger than 1 indicates a positive effect
of treatment.
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effect of temperature-lowering treatment.[14] Furthermore, the QASC trial showed
that early detection and management of fever (body temperature > 37.5°C), swal-
lowing difficulties and hyperglycaemia led to a significantly higher chance of being
alive or independent during follow up.[20] This trial was however not designed to
determine which of these interventions made the difference.
The results of PAIS 2 are neutral. However, because of serious lack of power
we cannot exclude an alternative result. We updated the previous meta-analysis
with the results of PAIS 2 (Figure 2.7) and found no significant difference between
temperature-lowering treatment and control in the proportion of patients who were
alive and independent (mRS2)(overall OR 1.04; 95% CI: 0.87 to 1.25). We also
performed a meta-analysis of data of all patients with a baseline temperature of
36.5°C or above (Figure 2.8), which showed comparable results (overall OR 1.08;
95% CI: 0.88-1.33). However, these analyses were binary and did not have the
advantage of ordinal regression analysis.
The main limitation of this study is that it was preliminary stopped and therefore
the study is strongly underpowered to detect a difference in functional outcome
after treatment with high-dose paracetamol in acute stroke. Patient recruitment was
low, which was most likely caused by the low intensity of trial coordination activities,
such as creating awareness for the study, providing information, feedback and
support to the participating centers. This was a consequence of the low budget.
The simultaneous conduct of several large randomized clinical trials of acute stroke
treatment in the Netherlands also added to the low recuitment rate. A strength of
the study is that it allowed us to update the meta-analysis with the results of this
study.
The results of PAIS 2 provide no evidence for the routine use of high dose
paracetamol in acute stroke. Although the relative effect may be low, an absolute
risk reduction in unfavorable outcome of 5% may be clinically relevant, considering
the large number of patients involved and the simple, safe, and cheap nature of
the therapy. Taking into account the results of the updated meta-analysis, such a
moderate effect could not be excluded. Further large clinical trials are necessary
to further explore this finding. This will be assessed in the trial PRECIOUS trial:
Prevention of Complications to Improve Outcome in elderly patients with Stroke
(www.precious-trial.eu).
Conclusion
Treatment with paracetamol after acute stroke appears safe. However, the effect
of treatment with high-dose paracetamol after acute stroke remains unclear. A
very large trial of early treatment with paracetamol after acute stroke is needed to
answer this question.
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Temperature as prognostic factor in stroke
Introduction
Treatment with intravenous alteplase is of proven benefit for patients with acute
ischemic stroke presenting within 4.5 hours after onset of symptoms.[1] In obser-
vational studies, high body temperature has been associated with unfavorable
outcome.[2] Physical cooling or prophylactic administration of antipyretic drugs
therefore appear promising treatment strategies.[3] In in vitro studies, the fibrinolytic
activity of alteplase decreased 5% per degree Celsius reduction in temperature,[4]
but the modifying effect of body temperature on thrombolytic treatment with al-
teplase in patients with acute ischemic stroke is unclear.[5] We assessed the
influence of baseline body temperature on the effect of intravenous alteplase on
functional outcome in patients with acute ischemic stroke, by analyzing data from
the Paracetamol (Acetaminophen) in Stroke (PAIS) trial.[6]
Methods
Patients
PAISwas amulticenter, randomized, double-blind, placebo-controlled trial to assess
the effect of high-dose paracetamol on functional outcome in patient with acute
stroke. The trial design and main results have been published elsewhere.[6] In
short, patients were eligible for inclusion in PAIS if they had ischemic stroke or
intracerebral hemorrhage and if start of treatment was possible within 12 hours
after onset of symptoms. Demographic data, medical history, score on the National
Institutes of Health Stroke Scale (NIHSS), rectal or tympanic temperature, treatment
with intravenous alteplase, time from onset of symptoms to start of treatment, and
functional outcome at 3 months, measured by the modified Rankin Scale (mRS),
were recorded. For the present analysis, we selected all patients with acute
ischemic stroke and randomization within 6 hours from onset, to take any delays
between treatment with alteplase and randomization into account.
Statistical analysis
We assessed the effect of treatment with alteplase on the score on the mRS at 3
months with multiple ordinal logistic regression analysis. We adjusted for age, sex,
baseline NIHSS score, previous stroke, atrial fibrillation, smoking, and diabetes
mellitus. We stratified for body temperature (<37.0°C vs.≥ 37.0°C). We also tested
for interaction between treatment with alteplase and body temperature. To estimate
the effect of treatment with paracetamol on the effect of alteplase, we used the
same type of analysis. We expressed associations as adjusted odds ratios (aOR)
with 95% confidence intervals (CI).
Results
Of the 1400 patients enrolled in PAIS, we included 647 (46%) in the present study.
The patients who were excluded from the present study had been included in
PAIS later than 6 hours after symptom onset (642 (46%)) or had intracerebral
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Abstract
Background
In observational studies, high body temperature has been associated with unfa-
vorable outcome. In in vitro studies, the fibrinolytic activity of alteplase decreased
5% per degree Celsius reduction in temperature. The modifying effect of body
temperature on treatment with alteplase in patients with acute ischemic stroke is
unclear. We assessed the influence of baseline body temperature on the effect of
alteplase on functional outcome in patients with acute ischemic stroke, included in
the Paracetamol (Acetaminophen) in Stroke (PAIS) trial.
Methods
PAIS was a randomized, double-blind clinical trial to assess the effect of high-dose
paracetamol on functional outcome in patients with acute stroke. For the present
study, we selected all patients with ischemic stroke and randomization within 6
hours of symptom onset. We estimated the effect of treatment with alteplase on the
modified Rankin Scale score at 3 months with ordinal logistic regression, stratified
by baseline body temperature. We made adjustments for confounding factors
and expressed associations as adjusted odds ratios (aOR) with 95% confidence
intervals (CI). We also tested for interaction between treatment with alteplase and
body temperature.
Results
Of the 1400 patients in PAIS, we included 647 in the present study. Treatment
with alteplase was associated with improved functional outcome at 3 months (aOR,
1.51; 95%CI, 1.09 to 2.08). In the 286 patients (44%) with a baseline body tem-
perature of 37.0°C or higher, alteplase was associated with a larger effect (aOR,
2.13; 95%CI, 1.28 to 3.45) than in patients with a temperature below 37.0°C (aOR,
1.11; 95%CI, 0.71 to 1.69). A test for interaction between body temperature and
alteplase did not reach statistical significance (p=0.18).
Conclusion
Patients with ischemic stroke and a high body temperature may have a larger
benefit of treatment with alteplase than patients with lower body temperatures.
These findings are in line with those from in vitro studies, in which lowering temper-
ature decreased the fibrinolytic activity of the enzyme alteplase. This interaction
should be explored further in randomized clinical trials of thrombolytic therapy or
modification of body temperature. Trials of therapeutic hypothermia should be
controlled for treatment with thrombolytics, and trials of thrombolytic treatment
should consider body temperature as a potential effect modifier.
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the VISTA database, no influence of body temperature on the effect of treatment
with alteplase could be demonstrated, although the point estimates of the effect
by temperature categories suggested an attenuation of the benefit of alteplase in
patients with either a high (>37.5°C) or a low (<35.5°C) body temperature.[7] The
effect of body temperature has not been assessed in randomized trials of alteplase
or in pooled analyses of these trials.
Our results suggest effect modification of the benefit of alteplase by body tem-
perature. An important question is whether this modification, if real, is relevant,
especially in planned and ongoing trials that aim at reducing body temperature. In
these trials, physical cooling or antipyretic treatment will be started after admin-
istration of alteplase. The plasma half-life of alteplase is very short (5 minutes),
but the half-life of the resulting alteplase-plasmine-fibrinogen complex may be
quite prolonged, and its activity may also be affected by body temperature.[8]
Antipyretic treatment with paracetamol lowers body temperature with only 0.26°C
and is therefore unlikely to reduce the benefit of alteplase.[6] We have confirmed
this hypothesis in our data, where we observed no interaction between paracetamol
and the effect of alteplase. We recently started a second multicenter, randomized
trial to confirm the benefit of high- dose paracetamol on functional outcome in
patients with a baseline body temperature of 36.5°C or higher,[9] observed in a
subgroup analysis of PAIS.
The present study has limitations. PAIS was not designed to assess the ef-
fects of treatment with intravenous alteplase on functional outcome, but of early
antipyretic treatment with high-dose paracetamol. Baseline characteristics were
therefore not balanced between the groups. However, our analyses were adjusted
for imbalances in baseline factors.
In conclusion, our study suggests that in patients with ischemic stroke, the ben-
efit of treatment with alteplase may depend on body temperature. This interaction
should be explored further in randomized clinical trials of thrombolytic therapy or
modification of body temperature. Trials of therapeutic hypothermia should be
controlled for treatment with thrombolytics, and trials of thrombolytic treatment
should consider body temperature as a potential effect modifier.
Table 2.6: Baseline characteristics by treatment with intravenous alteplase.
Patients treated
with alteplase
Patients not
treated with
alteplase
P-
value
Number of patients 215 432
Age, years (mean, SD) 67.1 (14.5) 72.3 (12.2) 0.00
Sex (male) 127 (59.1%) 247 (57.27%) 0.65
Body temperature on
admission (mean, SD)
36.8 (0.6) 36.9 (0.6) 0.36
Body temperature on
admission <37.0°C
117 (54.4%) 244 (56.5%) 0.62
NIHSS on admission
(median, IQR)
10 (5-16) 5 (3-10) 0.00
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hemorrhage (111 (8%)). Of the 647 included patients, 215 (33%) had been treated
with intravenous alteplase. These patients had on average more severe strokes,
more non-lacunar infarcts and less often atrial fibrillation and other co-morbidities
than patients who were not treated with alteplase (Table 2.6). In the group of
361 patients (55%) with a body temperature of 37.0°C or higher, 117 (32%) were
treated with intravenous alteplase. Of the 286 patients with a body temperature
below 37.0°C, this number was 98 (34%). There were no differences in baseline
characteristics between these groups. After adjustment for confounders, treatment
with alteplase was associated with improved functional outcome at 3 months (aOR,
1.51; 95% CI, 1.09 to 2.08) (Figure 2.9). In the patients with a baseline body
temperature of 37.0°C or higher, alteplase was associated with a larger benefit
(aOR, 2.13; 95%CI, 1.28 to 3.45) than in patients with a temperature below 37.0°C
(aOR, 1.11; 95%CI, 0.71 to 1.69). A test for interaction between body temperature
and alteplase did not reach statistical significance (p=0.18). The effect of alteplase
was similar in patients on high-dose paracetamol (332 patients) and those on
placebo (315 patients) (Figure 2.9).
0 0.5 1 1.5 2 2.5 3
aOR, 95% CI
Alteplase better
All patients
Body temperature
< 37.0 degrees Celsius 
≥ 37.0 degrees Celsius 
Treatment allocation
Paracetamol
Placebo
Alteplase worse
aOR (95% CI) Number  Interaction
of patients p value
1.51 (1.09-2.08) 647 
1.11 (0.71-1.69) 361 0.183
2.13 (1.28-3.45) 286
1.52 (0.97-2.33) 332 0.849
1.54 (1.02-2.33) 315
Figure 2.9: Association between treatment with alteplase and functional outcome
at 3 months for all patients and different subgroups (adjusted Odds Ratio (aOR)
with 95% Confidence Interval (CI)).
Discussion
This study suggests that in patients with ischemic stroke, the effect of treatment
with alteplase may be larger with higher body temperatures. Our results should
be interpreted with caution, as a formal (but not very sensitive) test for interaction
between body temperature and alteplase was not significant.
Our findings are in line with those from in vitro studies, in which lowering
temperature decreased the fibrinolytic activity of the enzyme alteplase. A pooled
analysis of these in vitro studies has suggested a 5% reduction in fibrinolytic activity
per degree Celsius decrease in temperature.[4]
The effect modification by body temperature of the effect of alteplase on func-
tional outcome in patients has remained unclear. In contrast to the commonly
observed inverse relation between body temperature and outcome after stroke,
high body temperature was associated with favorable outcome in an observational
study of 111 patients treated with alteplase.[5, 7] In a study of 5586 patients from
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with alteplase may be larger with higher body temperatures. Our results should
be interpreted with caution, as a formal (but not very sensitive) test for interaction
between body temperature and alteplase was not significant.
Our findings are in line with those from in vitro studies, in which lowering
temperature decreased the fibrinolytic activity of the enzyme alteplase. A pooled
analysis of these in vitro studies has suggested a 5% reduction in fibrinolytic activity
per degree Celsius decrease in temperature.[4]
The effect modification by body temperature of the effect of alteplase on func-
tional outcome in patients has remained unclear. In contrast to the commonly
observed inverse relation between body temperature and outcome after stroke,
high body temperature was associated with favorable outcome in an observational
study of 111 patients treated with alteplase.[5, 7] In a study of 5586 patients from
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Hypertension 86 (40.0%) 214 (49.5%) 0.06
Atrial fibrillation 25 (11.6%) 83 (19.2%) 0.02
Diabetes mellitus 20 (9.3%) 72 (16.7%) 0.01
Current smoking 80 (37.2%) 113 (26.2%) 0.06
Previous stroke 33 (15.4%) 93 (21.5%) 0.06
Previous myocardial
infarction
28 (13.0%) 55 (12.8%) 0.46
Peripheral artery disease 19 (8.8%) 58 (13.4%) 0.10
Stroke subtype (lacunar
infarct)
16 (7.4%) 88 (20.4%) 0.00
SD=standard deviation; NIHSS=National Institute of Health Stroke Scale;
IQR=interquartile range
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Unequal access to treatment with 
intravenous alteplase for women 
with acute ischemic stroke
Sex as prognostic factor in stroke
Introduction
A recent meta-analysis of 18 studies showed that women with acute ischemic
stroke are less likely to receive treatment with intravenous alteplase than men.[1]
As women account for at least 60% of all deaths due to stroke, sex differences in
treatment of acute stroke are important.[2] There are several hypotheses about
this sex disparity.[1] Women are generally older. Although age is not a contraindi-
cation for treatment,[3] physicians may be less inclined to treat older patients.
Women may more often have contraindications for thrombolysis, such as use of
oral anticoagulants.
So far, the lower treatment rate in women has not yet been explained. The
aim of the present study is to assess the differences between men and women in
treatment with intravenous alteplase, and to study reasons for this difference.
Methods
We analyzed data from the PRACTISE study; all individuals aged 18 and older
with acute stroke presenting within 24 hours of symptom onset were registered
in 12 hospitals in the Netherlands between 2003 and 2005. Patients presenting
within 4 hours were assessed in more detail. Stroke severity, assessed with the
National Institutes of Health Stroke Scale (NIHSS), was available in all patients
with an ischemic stroke presenting within 4 hours. The study protocol and main
results have been published elsewhere.[4, 5]
We defined outcome as treatment with rtPA in the total stroke population and in
the subgroup of patients with ischemic stroke presenting within 4 hours, and onset-
to-door time as the time from onset of symptoms to presentation and registration at
the emergency department (ED). We used a multivariable logistic regression model
with adjustment for age and expressed associations as adjusted odds ratios with
95% confidence intervals. We explored the effect of onset to door time, intervention
of a GP, and contraindications for treatment on the likelihood of being treated.
Results
A total of 5515 patients were included in the PRACTISE study, 2778 (50,4%)
women and 2737 men. On average, women were four years older than men. The
median NIHSS score was 6 in women and 5 in men (Table 3.1). Considering the
total population, fewer women were treated with intravenous alteplase (11% vs.
14%, OR 0.8; 95% CI: 0.7 to 0.9). Adjustment for age did not affect this association
(aOR 0.8; 95% CI: 0.7 to 1.0). In the 1657 ischemic stroke patients presenting
within 4 hours of stroke onset, the median NIHSS score was 6 in women and 5
in men (Table 3.1). Within this subgroup 41.6% women versus 42.4% men were
treated with intravenous alteplase (OR 1.0; 95% CI: 0.8 to 1.2) (Table 3.2).
Fewer women presented at the ED within 4 hours (27% vs. 33%, OR 0.8; 95%
CI: 0.7 to 0.9). After adjustment for age, the onset to door time in women was on
average 27 minutes longer (95% CI: 9 to 47 minutes). We found no differences in
sex-distribution in occurrence of hemorrhagic stroke, patients who called a GP or
63
Chapter 3
Abstract
Background and purpose
A recent meta-analysis showed that women with acute ischemic stroke are less
likely to receive treatment with intravenous alteplase than men. The aim of this
study is to assess sex differences in treatment with intravenous alteplase, and to
explore the reasons for these differences.
Methods
We analyzed data from the PRACTISE study. We applied a multiple logistic re-
gression model, and expressed the association between sex and treatment with
an age-adjusted odds ratio (aOR) with 95% confidence interval (CI).
Results
In total, 5515 patients were included in PRACTISE. Women were on average 4
years older than men. The median NIHSS score was 6 in women and 5 in men.
Fewer women were treated with intravenous alteplase (11% vs. 14%, aOR 0.8;
95% CI: 0.7 to 1.0). However, fewer women arrived within four hours after onset
(27% vs. 33%, aOR 0.8; 95% CI: 0.7 to 0.9).
Conclusions
Fewer women present themselves within four hours from stroke onset than men
and consequently receive less often thrombolytic treatment. This difference may
be caused by the on average older age of women and consequently women more
often living alone.
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GP’s were registered and therefore provides a good representation of the whole
population. The participating hospitals were representative in size, geographic
distribution and frequency of procedures.
Finally, the impact of sex differences in treatment of acute stroke is huge: almost
25% more women should be treated with alteplase in order to abolish the difference
and this number is increasing with the aging population. Therefore further research
is needed to understand the reasons why fewer women with acute stroke are
admitted in time for treatment to be able to deal with this inequality.
Table 3.2: Associations between sex and various characteristics, adjusted for age.
Women Men aOR (95% CI)
All patients (n=5515) n=2778
(50%)
n=2737
(50%)
Treatment with alteplase 314 (11%) 382 (14%) 0.8 (0.7 to 1.0)
GP called 1418 (51%) 1341 (49%) 1.0 (0.9 to 1.1)
GP visited 1209 (44%) 1124 (42%) 1.0 (0.9 to 1.1)
Onset to door time, min
(median, IQR)
427
(414-440)
391
(378-404)
0.7 (0.3 to 1.5)
Patients with ischemic
stroke presenting
within 4 hours from
onset (n=1657)
n=755
(46%)
n=902
(54%)
Treatment with alteplase 314 (42%) 382 (42%) 1.0 (0.8 to 1.2)
Contraindications for
treatment with alteplase
369 (49%) 449 (50%) 0.9 (0.8 to 1.1)
aOR=adjusted Odds Ratio; CI=confidence interval; GP=general practisioner;
IQR=interquartile range
References
[1] Reeves, M. et al. „Sex differences in the use of intravenous rt-PA thrombolysis
treatment for acute ischemic stroke: a meta-analysis”. Stroke 40 (2009),
1743–1749.
[2] Redon, J. et al. „Stroke mortality and trends from 1990 to 2006 in 39 countries
from Europe and Central Asia: implications for control of high blood pressure”.
European Heart Journal 32 (2011), 1424–31.
[3] Sandercock, P. et al. „The benefits and harms of intravenous thrombolysis
with recombinant tissue plasminogen activator within 6 h of acute ischaemic
stroke (the third international stroke trial [IST-3]): a randomised controlled
trial”. Lancet 379 (2012), 2352–63.
65
Chapter 3
Table 3.1: Baseline characteristics by sex.
Women Men
All patients (n=5515) n=2778 (50%) n=2737 (50%)
Age, years (mean, SD) 74 (13) 70 (12)
Age 80 years or above 1140 (41%) 605 (22%)
Patients with ischemic stroke presenting
within 4 hours from onset (n=1657)
n=755 (46%) n=902 (54%)
Age, years (mean, SD) 74 (13) 70 (12)
Hypertension 414 (55%) 434 (48%)
Atrial fibrillation 144 (19%) 153 (17%)
Diabetes mellitus 134 (18%) 140 (16%)
Hypercholesterolemia 285 (38%) 353 (39%)
Current smoking 138 (18%) 260 (29%)
Previous ischemic stroke 139 (18%) 193 (21%)
Previous myocardial infarction 63 (8%) 164 (18%)
NIHSS at admission (median, IQR) 6 (3-13) 5 (3-10)
SD=standard deviation; NIHSS=National Institute of Health Stroke Scale; IQR=
interquartile range
were visited by the GP, or had contraindications for treatment with alteplase (Table
3.2).
Discussion
Our study showed that women are treated just as often with thrombolytic agents
as men in the Netherlands, once they arrived in time for treatment. However, if
we consider the complete stroke care pathway, fewer women presented at the ED
within 4 hours of stroke onset. So far, this lower treatment rate in women has not
yet been clarified.[1] Our results suggest that this difference could be caused by
delayed presentation to the ED. This is also confirmed in other studies.[6] Also in
myocardial infarction there is an underutilization of thrombolytic therapy in women,
and a delay in care seeking.[7] Possible reasons for this delay are differences in
presenting symptoms and the on average older age of women. Older people more
often live alone [8] and suffer an unwitnessed stroke. Living alone makes care
seeking difficult and also delays the referral and diagnostic process.
This study has some limitations. Limited demographic details of the included
patients were available, therefore no assumptions on the influence of specific
symptoms on onset-to-door time could be made. Also the data are collected in
2003-2005, and therefore can be a little outdated. The strength of the present
study is that all patients in the participating centers and the intervention of the
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Chapter 3.2 
Is intra-arterial treatment for acute 
ischemic stroke less effective in 
women than in men?
Sex as prognostic factor in stroke
Introduction
Women in high-income countries have a higher lifetime stroke risk and higher stroke
mortality than men. Poor outcome after stroke is more frequent in women, which
may add to the anticipated increase in burden of stroke.[1] Female stroke survivors
are more likely to be disabled and single after stroke and are institutionalized
3.5 times more often than male survivors.[2] The sex-specific effects on stroke
incidence and outcome might be contributed to female physiology, which differs
from men in terms of coagulation, immunity and hormone exposure.[2] Recently,
intra-arterial treatment (IAT) with stent thrombectomy devices for acute ischemic
stroke (AIS) has been proven safe and effective.[3, 4, 5, 6, 7] In this study we aim
to assess if sex modifies the effect of IAT in AIS.
Methods
Detailed methods of the MR CLEAN trial have been described earlier.[3, 8] In short,
MR CLEAN was a multi-center randomized-controlled trial of IAT for AIS. Patients
were randomized to IAT plus usual care, or usual care alone. Eligible patients had a
proximal arterial occlusion in the anterior cerebral circulation that was confirmed on
vessel imaging and could be treated within 6 hours after symptom onset. Approval
was obtained from a central medical ethics committee and the research board of
each participating center, and all participants (or legal representatives) provided
written informed consent.
Outcome
The primary outcome measure was the score on the modified Rankin Scale (mRS)
at 90 days. Secondary outcome measures included 90-day functional indepen-
dence (mRS 0-2) and mortality. Radiological outcome measures included arterial
recanalization measured with the modified Thrombolysis in Cerebral Infarction
(mTICI) score on Digital Subtraction Angiography (DSA) and final infarct volume on
non-contrast CT (NCCT) at 5-7 days.[9] Safety parameters included hemorrhagic
complications, progression of ischemic stroke, recurrent ischemic stroke and death.
Symptomatic intracranial hemorrhage was defined as neurological deterioration
of 4 or more points on the National Institute of Health Stroke Scale (NIHSS) with
confirmed intracranial hemorrhage on neuroimaging.
Statistical analysis
The primary effect parameter was the adjusted common odds ratio (acOR) for
a shift in the direction of better outcome on the mRS, which was estimated with
multivariable ordinal logistic regression. We looked for interaction between sex
and treatment effect by adding a multiplicative term in the multivariable ordinal
logistic regression model. The acOR and all secondary effect variables were ad-
justed for pre-specified potential imbalances in major prognostic variables between
intervention and control group: age, NIHSS at baseline, time from onset to ran-
domization, previous stroke, atrial fibrillation, diabetes mellitus and internal carotid
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Abstract
Introduction
Stroke etiology and outcome after ischemic stroke differ between men and women.
We examined if sex modifies the effect of intra-arterial treatment (IAT) in a random-
ized clinical trial of IAT for acute ischemic stroke in the Netherlands (MR CLEAN).
Patients and methods
Primary outcome was the score on the modified Rankin Scale at 90 days. We
tested for interaction between sex and treatment and estimated treatment effect by
sex with multiple ordinal logistic regression, with adjustment for prognostic factors.
Results
All 500 patients were included in the analysis, 292 (58.4%) were men. Treatment
effect (adjusted common Odds Ratio) was 2.39 (95% Confidence Interval (CI)
1.55-3.68) in men and 0.99 (95%CI 0.60-1.66) in women (pinteraction=0.016). In
women, mortality was higher in the intervention group than in the control group
(24% vs 15%, p=0.07). Serious adverse events (SAE) occurred more often in
women than in men undergoing intervention. There were no differences in neuro-
imaging outcomes.
Discussion and conclusion
Contrary to other studies, we found a significant interaction between sex and treat-
ment effect in the MR CLEAN trial. Pooled analyses of all published thrombectomy
trials did not confirm this finding. In MR CLEAN, women seem to have a slightly
more unfavorable profile, causing higher mortality and more SAEs, but insufficient
to explain the absence of an overall effect. This suggests a play of chance and
makes it clear that IAT should not be withheld in women.
70
3Sex as prognostic factor in stroke
Introduction
Women in high-income countries have a higher lifetime stroke risk and higher stroke
mortality than men. Poor outcome after stroke is more frequent in women, which
may add to the anticipated increase in burden of stroke.[1] Female stroke survivors
are more likely to be disabled and single after stroke and are institutionalized
3.5 times more often than male survivors.[2] The sex-specific effects on stroke
incidence and outcome might be contributed to female physiology, which differs
from men in terms of coagulation, immunity and hormone exposure.[2] Recently,
intra-arterial treatment (IAT) with stent thrombectomy devices for acute ischemic
stroke (AIS) has been proven safe and effective.[3, 4, 5, 6, 7] In this study we aim
to assess if sex modifies the effect of IAT in AIS.
Methods
Detailed methods of the MR CLEAN trial have been described earlier.[3, 8] In short,
MR CLEAN was a multi-center randomized-controlled trial of IAT for AIS. Patients
were randomized to IAT plus usual care, or usual care alone. Eligible patients had a
proximal arterial occlusion in the anterior cerebral circulation that was confirmed on
vessel imaging and could be treated within 6 hours after symptom onset. Approval
was obtained from a central medical ethics committee and the research board of
each participating center, and all participants (or legal representatives) provided
written informed consent.
Outcome
The primary outcome measure was the score on the modified Rankin Scale (mRS)
at 90 days. Secondary outcome measures included 90-day functional indepen-
dence (mRS 0-2) and mortality. Radiological outcome measures included arterial
recanalization measured with the modified Thrombolysis in Cerebral Infarction
(mTICI) score on Digital Subtraction Angiography (DSA) and final infarct volume on
non-contrast CT (NCCT) at 5-7 days.[9] Safety parameters included hemorrhagic
complications, progression of ischemic stroke, recurrent ischemic stroke and death.
Symptomatic intracranial hemorrhage was defined as neurological deterioration
of 4 or more points on the National Institute of Health Stroke Scale (NIHSS) with
confirmed intracranial hemorrhage on neuroimaging.
Statistical analysis
The primary effect parameter was the adjusted common odds ratio (acOR) for
a shift in the direction of better outcome on the mRS, which was estimated with
multivariable ordinal logistic regression. We looked for interaction between sex
and treatment effect by adding a multiplicative term in the multivariable ordinal
logistic regression model. The acOR and all secondary effect variables were ad-
justed for pre-specified potential imbalances in major prognostic variables between
intervention and control group: age, NIHSS at baseline, time from onset to ran-
domization, previous stroke, atrial fibrillation, diabetes mellitus and internal carotid
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Abstract
Introduction
Stroke etiology and outcome after ischemic stroke differ between men and women.
We examined if sex modifies the effect of intra-arterial treatment (IAT) in a random-
ized clinical trial of IAT for acute ischemic stroke in the Netherlands (MR CLEAN).
Patients and methods
Primary outcome was the score on the modified Rankin Scale at 90 days. We
tested for interaction between sex and treatment and estimated treatment effect by
sex with multiple ordinal logistic regression, with adjustment for prognostic factors.
Results
All 500 patients were included in the analysis, 292 (58.4%) were men. Treatment
effect (adjusted common Odds Ratio) was 2.39 (95% Confidence Interval (CI)
1.55-3.68) in men and 0.99 (95%CI 0.60-1.66) in women (pinteraction=0.016). In
women, mortality was higher in the intervention group than in the control group
(24% vs 15%, p=0.07). Serious adverse events (SAE) occurred more often in
women than in men undergoing intervention. There were no differences in neuro-
imaging outcomes.
Discussion and conclusion
Contrary to other studies, we found a significant interaction between sex and treat-
ment effect in the MR CLEAN trial. Pooled analyses of all published thrombectomy
trials did not confirm this finding. In MR CLEAN, women seem to have a slightly
more unfavorable profile, causing higher mortality and more SAEs, but insufficient
to explain the absence of an overall effect. This suggests a play of chance and
makes it clear that IAT should not be withheld in women.
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artery terminus (ICA-T) occlusion, and reported with 95% confidence intervals
(CI). All statistical analyses were performed with Stata/SE 13.1 (StataCorp, Texas,
USA).
Table 3.3: Baseline characteristics by sex.
Women (n=208) Men (n=292)
Age, years (median, IQR) 68 (55-79) 64 (56-74)
Pre-stroke mRS 0 157 (75%) 247 (85%)
Pre-stroke mRS 1-2 38 (18%) 37 (13%)
Atrial fibrillation 60 (29%) 75 (26%)
NIHSS (median, IQR) 17 (14-21) 18 (15-22)
ICA-T occlusion 50 (24%) 84 (29%)
Time from onset to randomization, min
(median, IQR)
197 (149-258) 204 (153-262)
IQR=interquartile range; mRS=modified Rankin Scale; NIHSS=National
Institute of Health Stroke Scale; ICA-T=internal carotid artery terminus
Results
All 500 patients were included in the analysis, 292 (58.4%) were men. Women
were on average 4 years older than men and had a lower percentage mRS 0
before randomization and slightly more atrial fibrillation (Table 3.3). The overall
effect of intervention on shift on the mRS at 90 days was acOR 1.67 (95% CI; 1.21
to 2.30). The acOR was 0.99 (95%CI; 0.60-1.66) in women and 2.39 (95% CI;
1.55-3.68) in men (Figure 3.1). P-value for interaction was 0.016. In men, mortality
in the intervention group was lower than in the control group (15% vs 21% p=0.17),
whereas in women mortality was higher in the intervention group than in the control
group (24% vs 15%, p=0.07). Functional independence at 90 days was reached
in 36% men and 29% women (aOR in men 2.19 (95% CI; 1.24-3.87), in women
2.05 (95% CI; 0.96-4.35). For women, this results in violation of the proportional
odds assumption and a neutral common odds ratio. There were no differences in
revascularization (mTICI score) between women and men (both 59% mTICI 2B
or 3). In men, the difference in infarct volume was statistically significant (27ml,
p=0.01), whereas in women this was not (12ml, p=0.34). Women in the intervention
group experienced more serious adverse events, including recurrent stroke, than
controls (46% vs 36%, p=0.16; Table 3.4).
Discussion
We studied the interaction between sex and IAT and showed that men experienced
a major benefit from IAT in MR CLEAN, whereas we did not find a beneficial
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Figure 3.1: Effects of the intervention on the primary outcome in all patients (a),
women (b) and men (c).
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treatment effect in women. In women, the proportionality assumption required for
ordinal analysis was not met and the effect on reaching independence was offset
by an increase in mortality and severe disability. Moreover, women had a more
unfavorable risk profile with a lower percentage mRS 0 before randomization and
slightly more atrial fibrillation, and they experienced more serious adverse events
in the intervention group compared to men. However, this does not totally explain
the large difference in treatment effect, which suggests a play of chance.
Several studies have assessed sex differences in outcome recanalization and
functional outcome after IAT for AIS.[5, 7, 10, 11] However, these studies did not
report baseline characteristics by sex. Therefore we could not compare the baseline
characteristics of women in our study to the baseline profile of women in other
studies. None of these studies found differences in recanalization rate and favorable
outcome between women andmen. Pooled analyses of all published thrombectomy
trials also showed no difference between men and women in favorable outcome
after IAT.[12] The increased mortality and poor outcome among women compared
to men in MR CLEAN has no firm clinical or biological basis. These considerations
suggest that a play of chance is the plausible explanation for our findings, and
make it clear that IAT should not be withheld in women.
Table 3.4: Safety outcomes by sex and treatment allocation.
Women Men
Treatment
allocation
IAT
(n=98)
Control
(n=110)
p-
value
IAT
(n=135)
Control
(n=157)
p-
value
Death within 7
days
16
(16%)
6 (5%) 0.01 17
(13%)
21
(13%)
0.84
Death within 30
days
24
(24%)
16
(15%)
0.07 20
(15%)
33
(21%)
0.17
Any SAE 45
(46%)
40
(36%)
0.16 65
(48%)
73
(47%)
0.78
Hemicraniectomy 5 (5%) 3 (3%) 0.37 9 (7%) 6 (6%) 0.92
sICH 9 (9%) 4 (4%) 0.10 9 (7%) 13 (8%) 0.60
Recurrent stroke 6 (6%) 1 (1%) 0.04 7 (5%) 0 (0) 0.00
Progression of
stroke
20
(20%)
18
(16%)
0.45 26
(19%)
29
(19%)
0.64
IAT=intra-arterial treatment; SAE=serious adverse event; sICH=symptomatic
intracerebral hemorrhage
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Chapter 3.3
No sex differences in long-
term functional outcome after 
intracerebral hemorrhage
Sex as prognostic factor in stroke
Introduction
The rates of disability and mortality after spontaneous intracerebral hemorrhage
(sICH) are high. Although age, use of oral anticoagulation (OAC), hematoma
volume, sICH location and intraventricular hemorrhage (IVH) are known prognostic
factors,[1] evidence is conflicting about the influence of sex on outcome after
sICH.[2] Existing analyses showed varying results regarding sex differences in
outcome, some reporting a lower mortality in men,[3, 4] other an increased survival
rate in women[5, 6, 7] and there are also neutral findings.[8, 9] As sex-related
differences in patients with sICH may possibly confound clinical management
and prognostication of outcome, we for investigated sex differences in long-term
functional outcome after sICH.
Methods
We used data from a prospective hospital registry. Consecutive patients aged >
18 years with sICH admitted to the Department of Neurology of the University of
Erlangen-Nuremberg, Erlangen, Germany, from January 2006 until July 2014 were
included. We excluded patients with secondary etiologies (e.g. ICH related to tumor,
vascular malformations including aneurysms, trauma). The ethics committee at
the University of Erlangen-Nuremberg approved the study. Informed consent was
obtained from all patients, legal representatives, or closest relatives.
We retrieved data on demographics, prior comorbidities, stroke severity, and
treatment (including do not treat orders, defined as withhold or withdrawal of care
within 24 hours after diagnosis) from institutional electronic databases. ICH was
diagnosed using brain computed tomography (CT). Two neuroradiologists blinded
to clinical data assessed all CT-scans independently. Hematoma site was defined
as lobar, deep, or posterior fossa. Hematoma volume was measured using the
ABC/2 or ABC/3 formula, as appropriate.[10] Hematoma enlargement was defined
as described previously.[11]
As described previously,[11] we assessed functional outcome, defined as the
score on the mRS, and mortality by mailed questionnaires and semi-quantitative
telephone interviews 3months and 1 year after ictus. We defined favorable outcome
as mRS=0-3 and clinical improvement during follow-up as mRS at 1 year less than
mRS at 3 months.
Statistics
All statistical analyses were performed using SPSS version 20.0. We used multi-
variable regression models to adjust for the pre-specified prognostic factors age,
pre-stroke mRS score, use of OAC, Glasgow Coma Scale (GCS) score at admis-
sion, hematoma volume and IVH and expressed associations as (adjusted) odds
ratios (aOR) with 95% confidence intervals (CIs). In addition, we performed a
propensity score matching using a balanced, parallel, 1:1 ratio nearest-neighbor
approach.[11] The propensity score was calculated to balance parameters showing
relevant(p<0.1) sex-related differences.
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Abstract
Background
There is conflicting evidence about the influence of sex on outcome after sponta-
neous intracerebral hemorrhage (sICH) and the majority of the research focused
on mortality and short-term outcome only. We investigated sex differences in
long-term functional outcome after sICH.
Methods
We used data from a prospective hospital registry and included all consecutive
patients with ICH admitted to our institution between January 2006 until July 2014.
Functional outcome was assessed by modified Rankin Scale evaluated 3 and 12
months after ICH. We explored the influence of sex on long-term functional outcome
using multivariable regression models and additionally by means of propensity
score matching.
Results
We analyzed 823 patients, of whom 380 (46%) women. Women were on average 3
years older (p<0.001), men had more often deep hematomas (p=0.01). Unadjusted
mortality rates were significantly increased in women at 3 months (42% vs.35%;
OR 1.35; 95%CI 1.02-1.80). After adjusting for baseline prognostic factors there
were no differences between men and women in short- and long term mortality (OR
1.01; 95%CI 0.66-1.54 and OR 1.04; 95%CI 0.69-1.57, respectively) and short and
long term unfavorable outcome (OR 1.02; 95%CI 0.67-1.55 and OR 0.96; 95%CI
0.62-1.48, respectively).
Conclusion
We found no sex-related differences in long-term functional outcome in patients
with sICH. The apparently worse functional outcome in women can be explained
by differences in age.
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Discussion
This study investigated sex-related differences in long-term functional outcome in
a large cohort of sICH. We found that women with ICH are on average older than
men, whereas men more often had arterial hypertension and deep hemorrhages.
We found no sex-related differences in long-term functional outcome and mortality
in patients with sICH.
We confirmed previous studies suggesting men suffered more often from deep
ICH [12] and women were on average older than men.[13] As both age and IVH are
established parameters affecting outcome,[14] it is notable that a careful statistical
approach accounting for these prognostic factors has not been undertaken in
previous observational studies.[3, 4] When analyzing outcome, it is important to
control for do not treat orders. As shown in other studies,[13] women in our study
seem to have more often do not treat orders than men. In our study, this difference
could be fully explained by women’s higher age.
The results of this analysis are based on a single-center, hospital-based database.
Also, patients with incomplete follow-up or who refused participation were on aver-
age younger and had less severe strokes. Yet, the other baseline characteristics of
these patients did not differ compared with patients included in the study. Despite
these shortcomings the present study revealed sufficient evidence that there are
no outcome differences between women and men after sICH.
Conclusion
We found no sex-related differences in long-term functional outcome in patients
with sICH. The apparently worse functional outcome in women can be explained by
differences in age. Irrespective of possible future sex-specific treatments, it appears
that both men and women will be likely to benefit from further improvements in
clinical management and neither sex should be aﬄicted with worse prognosis after
sICH.
Table 3.5: Baseline characteristics by sex.
Women
(n=380)
Men
(n=443)
P-
value
Clinical characteristics
Age, years (mean, SD) 73 (12) 70 (12) <0.001
Pre mRS (median, IQR) 1 (0-2) 0 (0-2) 0.55
Hypertension 296 (78%) 369 (83%) 0.05
Atrial fibrillation 74 (19%) 106 (24%) 0.12
Use of oral anticoagulants 71(19%) 112(25%) 0.02
Previous stroke 65 (23%) 127 (29%) 0.49
GCS at admission (median, IQR) 12 (5-15) 13 (5-15) 0.37
NIHSS at admission (median, IQR) 15 (6-28) 12 (5-26) 0.06
Hemorrhage characteristics
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Results
We included 931 patients in this study. 108 patients had incomplete follow-up
data or refused participation. These patients were significantly younger and had
less severe strokes, however did not differ in the proportion of male sex. Of the
remaining 823 patients, 380(46%) were women. Clinical baseline characteristics
differed significantly between women and men (Table 3.5). Women were older
than men (p<0.001) and were less frequently on OAC (p=0.02). Men more often
had a history of arterial hypertension (p=0.05) and deep ICH (p=0.01). Women
tended to have more do not treat orders (p=0.07). After adjustment for age, this
difference disappeared (aOR=1.36;95%CI=0.93-2.01).
Mortality rates were increased in women at 3months and 12months (42%vs.49%
in women and 35%vs.42% in men; OR 1.35; 95%CI: 1.02-1.80 and OR 1.32; 95%CI
1.00-1.74, respectively (Table 3.6)). Functional outcome at 3 months and 1 year
did not show sex-specific differences. Women had a 4% (95%CI -3%-11%) higher
risk of unfavorable outcome at 1 year than men.
After adjustment for age, pre-stroke mRS score, use of OAC, GCS score at
admission, hematoma volume and IVH, the differences between men and women
in short- and long-term mortality disappeared (aOR 1.01; 95%CI 0.66-1.54 and
aOR 1.04; 95%CI 0.69-1.57, respectively). There were no differences in short- and
long-term unfavorable outcome (aOR 1.02; 95%CI 0.67-1.55 and aOR 0.96; 95%CI
0.62-1.48, respectively). In addition, we performed a propensity-score matching
and re-assessed long-term mortality and functional outcome. Both mortality and
long-term functional outcome of the propensity-matched cohort is displayed in
Figure 3.2 without evidence of significant differences between women and men.
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Figure 3.2: Distribution of functional outcome (mRS) of the propensity-score
matched cohort at 1 year.
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Table 3.5: Baseline characteristics by sex.
Women
(n=380)
Men
(n=443)
P-
value
Clinical characteristics
Age, years (mean, SD) 73 (12) 70 (12) <0.001
Pre mRS (median, IQR) 1 (0-2) 0 (0-2) 0.55
Hypertension 296 (78%) 369 (83%) 0.05
Atrial fibrillation 74 (19%) 106 (24%) 0.12
Use of oral anticoagulants 71(19%) 112(25%) 0.02
Previous stroke 65 (23%) 127 (29%) 0.49
GCS at admission (median, IQR) 12 (5-15) 13 (5-15) 0.37
NIHSS at admission (median, IQR) 15 (6-28) 12 (5-26) 0.06
Hemorrhage characteristics
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Results
We included 931 patients in this study. 108 patients had incomplete follow-up
data or refused participation. These patients were significantly younger and had
less severe strokes, however did not differ in the proportion of male sex. Of the
remaining 823 patients, 380(46%) were women. Clinical baseline characteristics
differed significantly between women and men (Table 3.5). Women were older
than men (p<0.001) and were less frequently on OAC (p=0.02). Men more often
had a history of arterial hypertension (p=0.05) and deep ICH (p=0.01). Women
tended to have more do not treat orders (p=0.07). After adjustment for age, this
difference disappeared (aOR=1.36;95%CI=0.93-2.01).
Mortality rates were increased in women at 3months and 12months (42%vs.49%
in women and 35%vs.42% in men; OR 1.35; 95%CI: 1.02-1.80 and OR 1.32; 95%CI
1.00-1.74, respectively (Table 3.6)). Functional outcome at 3 months and 1 year
did not show sex-specific differences. Women had a 4% (95%CI -3%-11%) higher
risk of unfavorable outcome at 1 year than men.
After adjustment for age, pre-stroke mRS score, use of OAC, GCS score at
admission, hematoma volume and IVH, the differences between men and women
in short- and long-term mortality disappeared (aOR 1.01; 95%CI 0.66-1.54 and
aOR 1.04; 95%CI 0.69-1.57, respectively). There were no differences in short- and
long-term unfavorable outcome (aOR 1.02; 95%CI 0.67-1.55 and aOR 0.96; 95%CI
0.62-1.48, respectively). In addition, we performed a propensity-score matching
and re-assessed long-term mortality and functional outcome. Both mortality and
long-term functional outcome of the propensity-matched cohort is displayed in
Figure 3.2 without evidence of significant differences between women and men.
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Figure 3.2: Distribution of functional outcome (mRS) of the propensity-score
matched cohort at 1 year.
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OR=Odds Ratio; CI=Confidence Interval; IQR=interquartile range; mRS=modified
Rankin Scale.
Adjustments are made for age, pre-stroke mRS score, OAC, GCS score at admission,
hematoma volume and IVH.
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Deep hemorrhage 143 (38%) 205 (46%) 0.01
Lobar hemorrhage 191 (50%) 198 (45%) 0.11
Posterior fossa hemorrhage 41 (11%) 34 (8%) 0.12
IVH only 5 (1%) 6 (1%) 0.96
ICH volume, ml (mean, SD) 14 (4) 12 (5) 0.47
IVH 196 (52%) 228 (52%) 0.99
GRAEB score (median, IQR) 1 (0-4) 0 (0-4) 0.88
Hematoma enlargement (n=602) 32 (10%) 48 (13%) 0.32
Treatment characteristics
Extra ventricular drainage 92 (24%) 132 (30%) 0.07
Ventilation 151 (40%) 202 (47%) 0.07
Hematoma evacuation 17 (5%) 28 (7%) 0.26
Do not treat orders 74 (19%) 56 (13%) 0.07
SD=standard deviation; mRS=modified Rankin Scale; IQR=interquartile range; GCS=
Glasgow Coma Scale; IVH=intraventricular hemorrhage; ICH=intracerebral hemorrhage.
Table 3.6: Univariable and multivariable outcome analysis.
Women
(n=380)
Men
(n=443)
Univariable
analysis,
OR(95%CI)
Multivariable
analysis,
OR(95%CI)
In hospital mortality 116
(31%)
111
(25%)
1.31
(0.97-1.79)
1.14
(0.73-1.79)
Functional outcome at 3
months, mRS (median,
IQR)
5 (3-6) 5 (3-6) 1.27
(1.00-1.63)
1.04
(0.77-1.41)
Unfavorable outcome at
3 months (mRS 4-6)
263
(70%)
285
(65%)
1.26
(0.94-1.69)
1.02
(0.67-1.55)
Mortality at 3 months 158
(42%)
153
(35%)
1.35
(1.02-1.80)
1.01
(0.66-1.54)
Functional outcome at 1
year, mRS (median,
IQR)
5 (3-6) 5 (2-6) 1.26
(0.98-1.62)
0.94
(0.68-1.30)
Unfavorable outcome at
1 year (mRS 4-6)
252
(66%)
276
(62%)
1.19
(0.89-1.59)
0.96
(0.62-1.48)
Mortality at 1 year 185
(49%)
185
(42%)
1.32
(1.00-1.74)
1.04
(0.69-1.57)
Improvement on mRS at
1 year
71
(19%)
88
(20%)
0.93
(0.65-1.31)
1.25
(0.81-1.92)
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OR=Odds Ratio; CI=Confidence Interval; IQR=interquartile range; mRS=modified
Rankin Scale.
Adjustments are made for age, pre-stroke mRS score, OAC, GCS score at admission,
hematoma volume and IVH.
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General discussion
General discussion
Introduction
In the past decades, acute stroke treatment has seen major improvements with
the introduction of standardized stroke-unit care and treatment with intravenous
alteplase (IVT) within 4,5 hours after ischemic stroke (IS).[1] As a result, case fatality
rates dropped and stroke mortality declined.[2] Recently, intra-arterial treatment
(IAT) bymeans of stent-thrombectomy for a proximal intracranial arterial occlusion in
patients with IS has been proven highly effective.[3] However, stroke continues to be
a major contributor to disability worldwide. It also forms a sizable economic burden
and the development of new treatment strategies remains crucial. Prognostic
factors are characteristics that may be used to more accurately predict outcome,
improve clinical knowledge and management and guide the development of new
treatments. Hence, gaining better knowledge of prognostic factors may improve
decision making, but it may also guide the development of new treatments. This
has been the topic of this thesis.
The primary aim of this thesis was to assess the effect of body temperature
management on functional outcome in patients with acute stroke. The secondary
aims were to investigate sex differences in acute management after ischemic
stroke (IS) and sex differences in long-term functional outcome after intracerebral
hemorrhage (ICH). In this chapter, I will summarize and explain the main findings
of my studies, put them in the context of existing literature, and discuss clinical
implications and provide recommendations for further research.
Body temperature as prognostic factor in stroke: the effect of
body temperature management on functional outcome in pa-
tients with acute stroke
Main results of the PAIS 2 trial
The primary aim of this thesis was to assess the effect of body temperature manage-
ment on functional outcome in patients with acute stroke. To answer this question,
we performed the Paracetamol (Acetaminophen) in Stroke 2 (PAIS 2) trial. PAIS 2
was a multicenter, randomized, double-blind, placebo-controlled clinical trial which
aimed to assess the effect of treatment with high-dose paracetamol on functional
outcome in patients with acute stroke and a body temperature of 36.5°C and above.
Patients with ischemic stroke or intracerebral hemorrhage who could be treated
within 12 hours after symptom onset were treated with paracetamol 6 grams per
day or matching placebo for 3 consecutive days. Primary outcome was defined as
the score on the modified Rankin Scale (mRS) at 3 months. Inclusion started in
December 2011 and the trial was preliminary ended on January 1st 2015 due to
slow recruitment and lack of funding. We included a total number of 256 patients
of whom 136 (53%) were allocated to paracetamol. Treatment with paracetamol
did not influence functional outcome at 3 months (OR 1.02; 95% CI: 0.7-1.6). After
adjustment for age, stroke severity (NIHSS at admission) and stroke type this
finding did not change. There were no cases of liver failure and infections were
evenly balanced between both groups. We concluded that treatment with parac-
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receiving paracetamol and 232 of 703 (33%) receiving placebo improved beyond
expectation (adjusted OR 1.20; 95% CI: 0.96-1.50). In a post-hoc analysis of
patients with a baseline body temperature between 37.0 and 39.0C treatment with
paracetamol was associated with improved functional outcome (adjusted OR 1.43;
95% CI: 1.02-1.97).[15] A previous meta-analysis using a dichotomized outcome
showed a trend towards a favorable effect of temperature-lowering treatment.[14]
The results of PAIS 2 can be considered neutral. However, because of serious
lack of power we cannot exclude an alternative result.
Current American AHA/ASA guidelines recommend the use of antipyretic drugs
when body temperature exceeds 38.0°C in patients with IS.[16] European (ESO)
guidelines do not make any recommendation for treating hyperthermia as a means
to improve outcome in patients with IS.[17] For patients with ICH there is insufficient
evidence from randomized controlled trials to make strong recommendations on
whether, when, and for whom preventive or early fever treatment should be given
after acute ICH.[18] The differences in American and European recommendations
may result from different objectives. The AHA/ASA guidelines aim for lowering
body temperature and relief of symptoms often accompanying fever, such as pain
and discomfort, whereas the ESO guidelines aim for better functional outcome.
Preliminary ending of the PAIS 2 trial
The PAIS 2 trial was preliminary ended, mainly because of slow recruitment of
patients. This was most likely caused by the low intensity of trial coordination
activities - a consequence of the low budget - and the simultaneous conduct of
several large randomized clinical trials of acute stroke treatment in the Netherlands.
The trial was started in anticipation of upcoming funding, which never appeared.
Stopping a trial may cause harm to several people involved.[19] Firstly, it may
cause physical and emotional disadvantage to enrolled study participants.[19] In
our trial, after inclusion was stopped, 3 month follow-up was completed. Physical
disadvantage due to preliminary stopping of the trial is therefore unlikely. However,
emotional disadvantage may have been caused to the study participants. They
may feel that they have been put at risk by participating in a trial that due to
preliminary stopping was underpowered to answer the research question. Secondly,
preliminary stopping a trial may cause harm to the researchers.[19] They lose the
time, money and efforts already invested in the trial. The researchers may be
disappointed to have lost the chance to help patients and gain positive trial results,
which can be published in a high end journal. They also may lose faith from
participating clinicians. However, stopping a trial may also result in benefit for the
reseachers.[19] They may have gained experience in developing and conducting
a clinical trial, which gives further clinical trials a higher success rate. Thirdly,
preliminary stopping a trial may cause harm to society.[19] One of the primary
goals of a clinical trial is to add knowledge to society. When a trial is ended early,
the results often remain unpublished. In our case, we presented the results at an
international stroke congress and will publish them shortly. In the end, every piece
of evidence from randomized trials will add to the general knowledge about the
particular treatment effect, and should therefore not be discarded.
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etamol after acute stroke is safe. However, the effect of treatment with high-dose
paracetamol on functional outcome after acute stroke remains unclear. We updated
a meta-analysis of all studies with paracetamol after acute stroke, but adding the
results of the PAIS 2 trial did not provide the final answer.
PAIS 2 trial in the context of other studies
Therapeutic hypothermia (TH) is an intentional reduction of body temperature
and has been assessed in several diseases, such as neonatal hypoxic-ischemic
encephalopathy, traumatic brain injury, myocardial infarction and cardiac arrest,
with varying results. TH reduces mortality without increasing major disability in term
and late preterm newborns with hypoxic ischemic encephalopathy.[4] In traumatic
brain injury, TH did not lead to lower mortality and unfavorable outcome rates at 3
or 6 months.[5] In myocardial infarction, TH did not result in smaller infarct sizes
or a reduction of major adverse cardiac events.[6] One study found a significant
reduction in the incidence of heart failure,[7] but this finding needs confirmation
in other studies. TH has been accepted as an effective treatment after cardiac
arrest.[8] The American Heart Association Guideline recommends to maintain a
constant temperature between 32.0 and 36.0°C for at least 24 hours in patients who
remain comatose after return of spontaneous circulation.[9] This recommendation
is based on 3 randomized controlled trials. Two of these trials, published in 2002,
reported increased survival and functional recovery with induced hypothermia to
32.0 to 34.0°C.[8, 10] These studies were nevertheless not accepted by the whole
field, due to a small sample size and the risk of bias. One of the topics of the
following debate was the optimal target temperature, and a more recent study
found no difference in mortality and neurological outcome between patients treated
with target temperature of 33.0°C and patient treated with a target temperature of
36.0°C.[11] Unfortunately, statistical testing for equivalence was not performed.
Methods for body temperature-lowering management can be categorized as
physical and pharmacological. Two types of physical cooling are surface cooling
and endovascular cooling. In case of surface cooling the skin is cooled with air
or fluids.[12] Endovascular cooling uses intravascular catheters to lower body
temperature. Endovascular cooling is more reliable and induction rates are quick,
but it is also more invasive and time consuming.[12] Prevention of shivering also
requires sedation protocols, which may lead to unwanted side effects as pneumonia.
Physical cooling to improve functional outcome after ischemic stroke has been
assessed in several trials. One of these trials is the recently published ICTus 2
Trial.[13] The ICTus 2 Trial was stopped early because of the approval of IAT for
ischemic stroke and the subsequent changes in standard ischemic stroke care.
The researchers found a trend toward more pneumonia in hypothermia treated
patients, the trial was however not designed and too small to assess an effect on
functional outcome. Further research is ongoing.
Six studies have been performed on pharmacological temperature reduction in
acute stroke. Five of these studies used paracetamol as antipyretic drug.[14] These
studies were, except for PAIS, small and designed to test safety and feasibility.
They showed no effect on outcome. In the PAIS trial, 260 of 697 (37%) patients
90
4General discussion
receiving paracetamol and 232 of 703 (33%) receiving placebo improved beyond
expectation (adjusted OR 1.20; 95% CI: 0.96-1.50). In a post-hoc analysis of
patients with a baseline body temperature between 37.0 and 39.0C treatment with
paracetamol was associated with improved functional outcome (adjusted OR 1.43;
95% CI: 1.02-1.97).[15] A previous meta-analysis using a dichotomized outcome
showed a trend towards a favorable effect of temperature-lowering treatment.[14]
The results of PAIS 2 can be considered neutral. However, because of serious
lack of power we cannot exclude an alternative result.
Current American AHA/ASA guidelines recommend the use of antipyretic drugs
when body temperature exceeds 38.0°C in patients with IS.[16] European (ESO)
guidelines do not make any recommendation for treating hyperthermia as a means
to improve outcome in patients with IS.[17] For patients with ICH there is insufficient
evidence from randomized controlled trials to make strong recommendations on
whether, when, and for whom preventive or early fever treatment should be given
after acute ICH.[18] The differences in American and European recommendations
may result from different objectives. The AHA/ASA guidelines aim for lowering
body temperature and relief of symptoms often accompanying fever, such as pain
and discomfort, whereas the ESO guidelines aim for better functional outcome.
Preliminary ending of the PAIS 2 trial
The PAIS 2 trial was preliminary ended, mainly because of slow recruitment of
patients. This was most likely caused by the low intensity of trial coordination
activities - a consequence of the low budget - and the simultaneous conduct of
several large randomized clinical trials of acute stroke treatment in the Netherlands.
The trial was started in anticipation of upcoming funding, which never appeared.
Stopping a trial may cause harm to several people involved.[19] Firstly, it may
cause physical and emotional disadvantage to enrolled study participants.[19] In
our trial, after inclusion was stopped, 3 month follow-up was completed. Physical
disadvantage due to preliminary stopping of the trial is therefore unlikely. However,
emotional disadvantage may have been caused to the study participants. They
may feel that they have been put at risk by participating in a trial that due to
preliminary stopping was underpowered to answer the research question. Secondly,
preliminary stopping a trial may cause harm to the researchers.[19] They lose the
time, money and efforts already invested in the trial. The researchers may be
disappointed to have lost the chance to help patients and gain positive trial results,
which can be published in a high end journal. They also may lose faith from
participating clinicians. However, stopping a trial may also result in benefit for the
reseachers.[19] They may have gained experience in developing and conducting
a clinical trial, which gives further clinical trials a higher success rate. Thirdly,
preliminary stopping a trial may cause harm to society.[19] One of the primary
goals of a clinical trial is to add knowledge to society. When a trial is ended early,
the results often remain unpublished. In our case, we presented the results at an
international stroke congress and will publish them shortly. In the end, every piece
of evidence from randomized trials will add to the general knowledge about the
particular treatment effect, and should therefore not be discarded.
91
Chapter 4
etamol after acute stroke is safe. However, the effect of treatment with high-dose
paracetamol on functional outcome after acute stroke remains unclear. We updated
a meta-analysis of all studies with paracetamol after acute stroke, but adding the
results of the PAIS 2 trial did not provide the final answer.
PAIS 2 trial in the context of other studies
Therapeutic hypothermia (TH) is an intentional reduction of body temperature
and has been assessed in several diseases, such as neonatal hypoxic-ischemic
encephalopathy, traumatic brain injury, myocardial infarction and cardiac arrest,
with varying results. TH reduces mortality without increasing major disability in term
and late preterm newborns with hypoxic ischemic encephalopathy.[4] In traumatic
brain injury, TH did not lead to lower mortality and unfavorable outcome rates at 3
or 6 months.[5] In myocardial infarction, TH did not result in smaller infarct sizes
or a reduction of major adverse cardiac events.[6] One study found a significant
reduction in the incidence of heart failure,[7] but this finding needs confirmation
in other studies. TH has been accepted as an effective treatment after cardiac
arrest.[8] The American Heart Association Guideline recommends to maintain a
constant temperature between 32.0 and 36.0°C for at least 24 hours in patients who
remain comatose after return of spontaneous circulation.[9] This recommendation
is based on 3 randomized controlled trials. Two of these trials, published in 2002,
reported increased survival and functional recovery with induced hypothermia to
32.0 to 34.0°C.[8, 10] These studies were nevertheless not accepted by the whole
field, due to a small sample size and the risk of bias. One of the topics of the
following debate was the optimal target temperature, and a more recent study
found no difference in mortality and neurological outcome between patients treated
with target temperature of 33.0°C and patient treated with a target temperature of
36.0°C.[11] Unfortunately, statistical testing for equivalence was not performed.
Methods for body temperature-lowering management can be categorized as
physical and pharmacological. Two types of physical cooling are surface cooling
and endovascular cooling. In case of surface cooling the skin is cooled with air
or fluids.[12] Endovascular cooling uses intravascular catheters to lower body
temperature. Endovascular cooling is more reliable and induction rates are quick,
but it is also more invasive and time consuming.[12] Prevention of shivering also
requires sedation protocols, which may lead to unwanted side effects as pneumonia.
Physical cooling to improve functional outcome after ischemic stroke has been
assessed in several trials. One of these trials is the recently published ICTus 2
Trial.[13] The ICTus 2 Trial was stopped early because of the approval of IAT for
ischemic stroke and the subsequent changes in standard ischemic stroke care.
The researchers found a trend toward more pneumonia in hypothermia treated
patients, the trial was however not designed and too small to assess an effect on
functional outcome. Further research is ongoing.
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General discussion
Analog with TH in cardiac arrest it seems rational to aim for a temperature of
33.0-34.0°C. Temperatures of 36.0-36.5°C may be still as effective.[11]
To shorten the time window from onset of stroke symptoms and initiation of
treatment, pre-hospital administration of neuroprotective agents may be an inter-
esting approach. Paracetamol is an attractive candidate drug for this approach,
because both patients with IS and ICH may profit from treatment with paracetamol.
Radiological assessment preceding treatment is not necessary and patients could
be given paracetamol during transportation to the hospital.[26]
The effect of pharmacological temperature reduction with paracetamol is small
and might be combined with other neuroprotective agents to increase the neuro-
protective effects. The processes taking place in the human brain are extremely
complicated and multiple pathways are involved, for example the release of ex-
citatory amino acids, formation of free radicals, increased metabolic demands,
activation of the immune system and increased blood-brain barrier permeabil-
ity.[20] It seems therefore reasonable to combine multiple drugs targeting different
pathways and processes. An example of this strategy might be a combination
of paracetamol and metoclopramide, a gastric prokinetic drug,[27] or metformin,
which has anti-inflammatory effects.[28] The combination of first two drugs will be
assessed in the PRECIOUS trial. It should be noted that assessing interactions in
a factorial design results in the need of a very large study population.
A promising new physical cooling method is intra-arterial cooling in case of
succesfull IAT.[29] This method combines IAT with local intra-arterial infusion of
a cold saline bolus into the cerebral arteries. The safety and feasibility has been
shown in a previous study.[29] Randomized clinical trials are needed to investigate
the efficacy of this therapy.
Sex as prognostic factor in stroke: sex differences in acute
management after ischemic stroke and long term functional out-
come after ICH
Main results
The secondary aims of this thesis were to investigate sex differences in acute
management of IS and functional outcome after ICH. We showed that women
receive less often IVT due to a later presentation to the emergency department.[30]
In addition, we found a significant interaction between sex and treatment effect
of intra-arterial treatment (IAT) in the MR CLEAN trial.[31] Pooled analyses of all
published thrombectomy trials did not confirm this finding.[32] Finally, we detected
no sex-related differences in long term functional outcome after ICH.[33]
Sex differences in stroke
The role of sex in stroke is complicated. The interaction between characteristics
that differ between women and men (sex hormones, coagulation, immune system),
risk factors more common in women (atrial fibrillation, metabolic syndrome, mi-
graine), risk factors unique for women (use of contraceptives, hormonal changes,
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Implications of PAIS 2
With the PAIS 2 trial we confirmed that treatment with paracetamol is safe. There
were no cases of liver failure; infections and other adverse events were evenly
balanced between both groups. However, a small chance of liver failure still exists
and may offset the possible treatment effect of paracetamol. The results of the
trial could not confirm our hypothesis. Also, adding our results to the latest meta-
analysis of all paracetamol trials could not answer the research question definitively.
The question is how to proceed after PAIS 2. There is insufficient evidence to
suggest routine use of high-dose paracetamol in patients with acute stroke and
a body temperature of 36.5°C and above. As more severely affected patients
may profit more from treatment with paracetamol, and this finding is biological
plausible,[20] the PRECIOUS (Prevention of Complications to Improve Outcome in
elderly patients with Stroke) trial has just started. This study will assess the effect
of preventive treatment with paracetamol, metoclopramide and ceftriaxone on a
comprehensive array of relevant health outcomes in a factorial design. The study
will focus on elderly patients with a score on the NIHSS of 6 or higher.
Recommendations for further research
Further research on body temperature-lowering management is warranted. Im-
portant factors that influence the neuroprotective effect of temperature-lowering
management include the time window before treatment is initiated, the duration
of treatment, and depth of body temperature-lowering management.[21] The time
window between stroke onset and initiation of treatment should be as short as
possible. The central concept in the processes taking place in ischemic brain
tissue is that of the ischemic penumbra. This part of the ischemic brain tissue
suffers from restricted blood supply, but is still capable of survival when reperfu-
sion is achieved in a certain period of time.[22] Reperfusion is therefore crucial
to protect the brain from permanent damage and should be achieved as soon
as possible, as other forms of neuroprotection only can achieve success in not
permanently damaged brain tissue. Consensus in stroke literature is that most of
the permanent brain damage arising from focal ischemia occurs within a few hours
time period. This consensus is based on the narrow therapeutic window of a few
hours of neuroprotective drugs shown in rodent models, the rapid progression of
brain damage seen on CT or MRI, and the rapid reduction with time of the efficacy
of alteplase- and trombectomy-induced reperfusion.[21] The optimum duration of
body temperature lowering management is unknown. Previous studies suggested
that a longer duration confers better neuroprotection.[21] However, a longer dura-
tion may be associated with a higher rate of pneumonia.[23] Finally, the optimal
depth of body temperature-lowering management is also unknown. Animal studies
have shown that cooling to 27.0°C showed less reduction in total infarct volume
than cooling to a temperature of 32.0°C,[24] suggesting that cooling may not be too
deep. Moreover, improved functional outcome was found in animals with a target
temperature of 33.0-34.0°C compared with other temperatures.[25] In humans the
optimal depth of body temperature-lowering management is however unknown.
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Stroke symptoms
Stroke symptoms may differ between men and women. Women are more likely
to have impaired consciousness,[42, 43, 44] aphasia[42, 44] and visual field
disturbances.[42] These symptoms, in combination with women’s higher age and
social situation (more often living alone), make care seeking difficult and lead to
pre-hospital delays and fewer treatment possibilities. Women may also experience
more nonspecific symptoms as pain, headache, behavioral changes and vision
changes.[45] Women, caregivers and health care providers could be trained to
recognize these differences. A real-life example for this is aphasia. Aphasia may
be easily misdiagnosed as confusion. A simple screening test is able to distinguish
between both, is easy to implement and may lead to a faster recognition of stroke
in women. Sex differences in presenting symptoms are also found in patients with
acute myocardial infarction. Compared to men, women present less often with
the typical symptoms chest pain and arrhythmia and wait longer before seeking
treatment.[46] The explanation for these differences in presenting symptoms in
both stroke and myocardial infarction is unknown and further research is needed.
Utilization of treatment
Women seem to be treated less often with IVT than men.[36, 47] A meta-analysis
of 16 studies found that women are 25% less likely to be treated with IVT than
men, although a significant between-study variation existed. More recent studies
showed limited sex difference in the utilization of treatment, with again variable
findings.[36] We found that women receive IVT less often because they present
less often to the emergency department within 4 hours from stroke onset.[30] This
delay could be explained by differences in presenting symptoms (as described
above) and women’s older age. Women live longer than men and are on average
older when having a stroke.[2] Older people more often live alone and experience
unwitnessed stroke. Living alone makes care seeking difficult and also delays
the referral and diagnostic process. Unfortunately, these factors are not easily
addressed. Solutions may be found in personal devices that send alarms through
the internet when needed.
Efficacy of treatment
Women seem to benefit more from treatment with IVT than men.[36] A pooled
analysis of 3 randomized controlled trials of IVT showed that the proportion of men
and women having a favorable outcome following treatment with IVT was similar
(38.5% vs. 40,5%). However, among the placebo groupmen had significantly better
outcomes (favorable outcome in men 36.7%, women 30.3%). These data suggest
a significant interaction between sex and IVT, with women having a substantial
greater benefit from IVT than men.[48] There are several possible explanations for
the interaction between sex and IVT response. The first explanation is that women
have an increased recanalization rate after following IVT. This is believed to be
due to a reduced arterial size,[49] resulting in smaller clots, and estrogen-related
differences in levels of clotting factors.[48] Women also have cardio-embolic stroke
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pregnancy, pregnancy-induced hypertension, child birth, menopause) and social
factors is very complex.[34] All these factors act together to cause stroke. Women
live longer than men, resulting in a higher life time risk of stroke in women than
in men (20% vs. 17%).[34] Women also experience other stroke types, with sub-
arachnoid hemorrhage and cerebral venous thrombosis being more common in
women; and other ischemic stroke subtypes, with large vessel strokes being more
common in women.[35] Moreover, sex may influence treatment. Both the efficacy
and utilization of treatment may differ between women and men.[36] Finally, all the
above-mentioned factors determine outcome after stroke. Women have poorer
functional outcomes, are more often institutionalized, more often have depression
and a lower quality of life after stroke.[34, 35, 37, 38] It is unclear whether this
difference is caused by women’s higher age, poorer prestroke functions and ten-
dency to have more severe strokes or whether other factors, like differences in
stroke presentation, acute management, effects of therapies and social factors as
not being able to perform care-giver activities, also play a role. As the burden of
stroke is higher in women than in men, these are important issues to be addressed.
I will discuss some of these factors in detail below.
Estrogens
When discussing sex differences in stroke, the role of estrogens must be addressed.
Estrogen is the primary female sex hormone. It is responsible for the development
and regulation of the female reproductive system and secondary sex characteristics.
Estrogens diffuse easily through the plasma membrane and form complexes with
estrogen receptors.[39] These receptors are present in both men and women and
are widely distributed in many organs, including the cardiovascular system. In
the cardiovascular system they cause the production of endothelial factors, such
as nitric oxide, opening of potassium channels and activation of numerous signal
transduction cascades, leading to rapid vasodilation. With this, estrogens play
a role in blood pressure regulation and appear to be an important factor in the
development of hypertension and cardiovascular diseases.[39] Hormonal levels
change after menopause and the synthesis of estrogens is decreased and stroke
risk seems to increase after menopause.[40] In observational studies, hormone re-
placement therapy (HRT) was reported to reduce the risk of arterial vascular events.
A systematic review found however that HRT is associated with an increased risk
of cardiovascular disease, stroke and venous thromboembolism.[41] The reasons
for these unexpected findings have been discussed comprehensively. Factors
that might have contributed are the age of the patients, preexisting cardiovascular
diseases, age of HRT initiation, type of HRT (mono or combination therapy) and
dosage.[39] Prospective studies on the influence of HRT on blood pressure in
postmenopausal women were so far inconclusive. In spite of the potential beneficial
effects of estrogens, their mechanisms of action and interaction seem to be more
complex when it comes to therapy applications and therefore additional research
is needed. Knowledge of these mechanisms in the cardiovascular system may
contribute to the development of new therapies with sex hormones.
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differences and therefore it may be rational to use both male and female animal
models in basic scientific research. If interventions fail in one sex but are effective
in the other, it would be interesting to determine the nature of the difference at
molecular levels. Another interesting field would be to assess the neuroprotective
effects of sex steroids. Estrogens are thought to cause vasodilatation and have
other neuroprotective effects. However, hormone replacement therapy (HRT)
does not reduce stroke risk. By contrast, it raises stroke risk. The use of oral
contraceptives is associated with a 2-fold increase in IS risk.[50] This increase may
be caused a high estrogen dose, but even more by the addition of progresteron.[50]
This suggests a more complex interaction between sex steroids. Research on
the neuroprotective effects of sex steroids may focus on different stroke subtopics,
such as coagulation, the vascular system, the immune system and genetics. This
research could take place in animals, but probably the best categories are women
with the highest hormone levels, such as patients on HRT and pregnant women.
In clinical research, women need to be included in clinical trials in sufficient
numbers to provide power for preplanned subgroup analysis. Unfortunately, women
and other minorities are less likely to consent to participate in research studies.
As discussed earlier, women may suffer from aphasia and a lower level of con-
sciousness more often, making asking for consent more difficult. In many cases a
proxy consent is needed. Families tend to fear about making the right decision,
because they are in charge of someone’s life.[51] It would be interesting to assess
if trained researchers achieve higher consent rates. Finally, it would be interesting
to develop a sex-specific prediction model to predict outcome after acute stroke.
Most likely, a female and male model will be needed to incorporate all important
prognostic factors. This model could be used to inform patients and proxies about
prognosis, to plan discharge destination and to select patients for new treatment
strategies.
Conclusion
In this thesis I have focused on temperature and sex as prognostic factors in stroke.
Reducing body temperature after acute stroke seems an promising therapeutic
approach and may be performed in different ways. Patients with more severe
strokes may profit most from this therapy and further research will focus on that
subgroup of acute stroke patients. The role of sex in the prognosis of acute
stroke is very complex. Social factors rather than biological factors may explain
sex differences in acute stroke. As stroke continues to be a major contributor to
disability and economic burden of disease, it is extremely important to improve
existing management strategies and therapies and to find new approaches to solve
sex disparities. And that is vital, as anyone can suffer a stroke at any time.
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more frequently, which clots seem to be richer in fibrin. The exact mechanisms
of this interaction are however unknown. An interaction between sex hormones
and IVT could also be one of the reasons. Concerning women’s lower likelihood of
receiving IVT, there is a huge challenge for health care providers and the health
care system to increase the proportion of women treated with IVT.
In the MR CLEAN trial, a multicenter randomized-controlled trial of intra-arterial
treatment for IS, we found a significant interaction between sex and treatment
effect, with men receiving a greater benefit from IAT than women.[31] This finding
may be explained by a more unfavorable risk profile with a lower percentage mRS
0 before randomization and slightly more atrial fibrillation in women in MR CLEAN,
and more serious adverse events in women in the intervention group compared to
men. The increased mortality and poor outcome among women compared to men
in the MR CLEAN trial has no firm clinical or biological basis. Pooled analyses of
all published thrombectomy trials did not confirm this sex difference.[32] These
considerations suggest that a play of chance is the most plausible explanation for
our findings and make it clear that IAT should not be withheld from women.
Implications
The role of sex in stroke remains very complex. Over the past years, attention for
sex-specific differences in stroke has grown. The 2014World Stroke Day themewas
“I am woman: stroke affects me”. Aim of this day was to raise awareness among
women about stroke and stroke symptoms. Women have a higher life time risk of
stroke than men, but are also the main caregivers in the majority of patients. The
Women Initiative for Stroke in Europe (WISE) is a European Stroke Organization
(ESO) Working Group to guarantee better stroke care for women. WISE promotes
scientific initiatives to improve women’s stroke care. Further research is needed on
many topics. I will discuss some of them in the section below. Women are less likely
to be treated for risk factors than men.[34] To reduce this gap, sex-specific stroke
guidelines have been published in recent years. As an example, the American
Heart Association/ American Stroke Association published the “guideline for the
prevention of stroke in women.”[34] This guideline focuses on risk factors unique
for women, such as reproductive factors, hormonal conception, and pregnancy,
and gives sex-specific recommendations. We performed two studies that focused
on differences in acute treatment of IS and showed that once in hospital, women
are treated as often as men with IVT and that there are no reasons to withhold IAT
in women. Health care providers should be aware of sex-specific differences in
presentation, however they do not have to keep in mind sex-specific differences in
acute treatment.
Recommendations for further research
Further research on sex-specific differences in stroke is required. To start with basic
scientific research, I would recommend to test all interventions in both male and
female animal models. Usually most of the animals are male and the translation
from animal models to patients often fails. This may be caused by sex-related
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Summary/samenvatting 
Summary/samenvatting
English summary
Anyone can suffer a stroke at any time and the consequences of stroke are often
severe. As the incidence of stroke rises with age, and as population is aging,
the burden of stroke is expected to increase further, especially among elderly
women. Women also seem to have a higher chance to die from stroke and to
have less favorable outcomes. Prognostic factors are characteristics that may be
used to more accurately predict outcome, may improve clinical knowledge and
management and may guide new therapies. It remains an important challenge to
find new prognostic factors and to further evaluate and explore known prognostic
factors. This thesis focusses on the effect of body temperature lowering therapy
in acute stroke. The secondary aims are to investigate sex differences in acute
management of ischemic stroke (IS) and sex differences in long term functional
outcome after intracerebral hemorrhage (ICH).
Chapter 2 describes body temperature as prognostic factor in stroke. In Chapter
2.1 and 2.1 I describe the rationale, background, design and results of the Parac-
etamol (Acetaminophen) in Stroke 2 (PAIS 2) trial. Subfebrile body temperature
and fever in the first days after stroke are strongly associated with unfavorable
outcome. Lowering body temperature and prevention of fever are therefore in-
teresting approaches to improve functional outcome after stroke. Paracetamol is
one the most commonly prescribed antipyretic drugs. Treatment with high-dose
paracetamol induces a reduction in body temperature of about 0.3 degrees Celsius
in patients without fever. The Paracetamol (Acetaminophen) in Stroke (PAIS) trial
suggested that early treatment with high-dose paracetamol might improve func-
tional outcome in patients with a body temperature of 36.5°C and higher (OR 1.31;
95% CI: 1.01–1.97). As this result was based on a posthoc analysis, confirmation
in an independent study was needed. Hence, the aim of PAIS 2 was to assess
the effect of high-dose paracetamol on functional outcome in patients with acute
stroke and a body temperature of 36.5°C and above in the first 12 hours after
stroke onset.
PAIS 2 was a multicenter, randomized, double blind, placebo-controlled clinical
trial. We aimed to include 1500 patients with acute ischemic stroke or intracere-
bral hemorrhage within 12 hours of symptom onset. Patients were treated with
paracetamol in a daily dose of 6 g or matching placebo for 3 consecutive days.
The primary outcome was improvement on the modified Rankin Scale score at
3 months, assessed with multivariable ordinal logistic regression. Due to slow
recruitment and lack of funding the study was stopped prematurely. Between
December 2011 and October 2015, we included 256 patients, of whom 136 (53%)
were allocated to paracetamol. We found no significant effect of paracetamol on the
shift of scores on the mRS (acOR 1.02; 95% CI: 0.7-1.6). There was no difference
in serious adverse events (paracetamol n=35 (26%) versus placebo n=28 (24%)).
We concluded that treatment with paracetamol after acute stroke is safe. The effect
of treatment with high-dose paracetamol on functional outcome after acute stroke
remains however uncertain. A very large trial of early treatment with paracetamol
after acute stroke is needed to provide more precise effect estimates.
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In Chapter 2.3, I assess the influence of baseline body temperature on the
effect of alteplase on functional outcome in patients with acute ischemic stroke.
In in vitro studies, the fibrinolytic activity of alteplase decreased 5% per degree
Celsius reduction in temperature, but the modifying effect of body temperature on
thrombolytic treatment with alteplase in patients with acute ischemic stroke was
unclear. I found that the effect of treatment with alteplase may be larger with higher
body temperatures. As a consequence, trials of therapeutic hypothermia should be
controlled for treatment with alteplase, and trials of thrombolytic treatment should
consider body temperature as a potential effect modifier.
Chapter 3 describes sex as prognostic factor in stroke. Chapter 3.1 discusses
sex disparities in utilization of intravenous trombolytic therapy (IVT). We found that
women are treated just as often with IVT as men in the Netherlands, once they
arrived in time for treatment. However, if we consider the complete stroke care
pathway, fewer women present themselves within four hours from stroke onset
than men and consequently receive less often IVT. This difference may be caused
by the on average older age of women and consequently women more often living
alone.
Chapter 3.2 describes sex differences in functional outcome after intra-arterial
treatment (IAT) for IS. We showed that men experienced a major benefit from IAT in
MR CLEAN, whereas we did not find a beneficial treatment effect in women. This
finding has no firm clinical or biological basis. Women seemed to have a slightly
more unfavorable profile, causing higher mortality and more serious adverse events.
Pooled analyses of all published thrombectomy trials showed indeed no difference
between men and women in favorable outcome after IAT. These considerations
suggest that a play of chance is the plausible explanation for our findings, and
make it clear that IAT should not be withheld in women.
In Chapter 3.3, I investigate sex differences in long-term functional outcome after
spontaneous ICH (sICH). We analyzed data from 823 patients from a prospective
hospital registry and found that women with ICH are on average older than men,
whereas men more often had arterial hypertension and deep hemorrhages. There
were no sex-related differences in long-term functional outcome and mortality
in patients with sICH. The apparently worse functional outcome in women can
be explained by differences in age. Irrespective of possible future sex-specific
treatments, it appears that both men and women will be likely to benefit from further
improvements in clinical management and neither sex should be aﬄicted with
worse prognosis after sICH.
In chapter 4, I summarize and explain the main findings of my studies described
in this thesis, discuss clinical implications and provide recommendations for further
research. I start with a discussion about the results and implications of the PAIS 2
trial. I discuss the various forms of hypothermia and results of previous studies.
Next I discuss sex as prognostic factor in stroke, describing the role of estrogens
and sex differences in stroke symptoms, utilization and efficacy of IVT. I end with
the conclusion that further research on both subjects is needed in order to develop
new treatment strategies that reduce health and economic burden of stroke. And
that is vital, as anyone can suffer a stroke at any time.
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Summary/samenvatting
Nederlandse samenvatting
Iedereen kan op elk moment een beroerte krijgen, en de gevolgen van een beroerte
zijn vaak ernstig. Doordat de incidentie van beroertes toeneemtmet de leeftijd en de
bevolking steeds ouder wordt, nemen de gevolgen van beroertes steeds verder toe,
voornamelijk onder vrouwen. Dit komt doordat de mortaliteit van beroertes hoger
is bij vrouwen dan bij mannen en doordat vrouwen een grotere kans hebben op
een slechte functionele uitkomst. Prognostische factoren zijn factoren die gebruikt
kunnen worden om uitkomst te voorspellen, tevens kunnen ze behandelingen
verbeteren en richting geven aan de ontwikkeling van nieuwe therapieën. Het doel
van dit proefschrift is het effect van lichaamstemperatuur verlagende therapie bij
patiënten met een acute beroerte te onderzoeken. Subdoelen zijn het onderzoeken
van sekseverschillen in de behandeling van herseninfarcten en in lange termijn
uitkomst na een hersenbloeding.
Hoofdstuk 2 beschrijft lichaamstemperatuur als prognostische factor bij beroertes.
In paragraaf 2.1 en 2.2 beschrijf ik de rationale, achtergrond, het design en de
resultaten van het Paracetamol (Acetaminophen) in Stroke 2 (PAIS 2) onderzoek.
Subfebriele lichaamstemperatuur en koorts in de eerste dagen na een beroerte zijn
sterk geassocieerd met slechte functionele uitkomst. Het verlagen van de lichaam-
stemperatuur en het voorkomen van koorts zouden daarom het functioneel herstel
na een beroerte kunnen verbeteren. Paracetamol is het meest voorgeschreven
middel bij koorts. Uit eerder onderzoek bij mensen zonder koorts weten we dat
paracetamol de lichaamstemperatuur kan verlagen met 0.3 graden Celsius. Het
eerste Paracetamol (Acetaminophen) in Stroke (PAIS) onderzoek vond dat vroege
behandeling met hoge doseringen paracetamol de functionele uitkomst na een
beroerte mogelijk verbetert bij patiënten met een lichaamstemperatuur van 36.5°C
en hoger (OR 1.31; 95% CI: 1.01–1.97). Deze resultaten waren gebaseerd op
een posthoc gedefinieerde subgroep analyse, en daarom was bevestiging van
de resultaten in een onafhankelijk onderzoek nodig. Het doel van PAIS 2 was te
onderzoeken of behandeling met hoge dosering paracetamol effect heeft op func-
tionele uitkomst bij patiënten met een acute beroerte en een lichaamstemperatuur
van 36.5°C en hoger.
PAIS 2 was een multicenter, gerandomiseerd, dubbelblind, placebogecon-
troleerd onderzoek. Het doel was het includeren van 1500 patiënten met een
acuut herseninfarct of hersenbloeding binnen 12 uur na het ontstaan van de symp-
tomen. Patiënten werden behandeld met 6 gram paracetamol per dag of placebo
gedurende 3 opeenvolgende dagen. De primaire uitkomstmaat was verbetering
op de modified Rankin Scale (mRS) score gemeten na 3 maanden en geanal-
yseerd met multivariabele ordinale regressie. Het onderzoek werd vroegtijdig
afgebroken in verband met langzame inclusie van patiënten en een tekort aan
financiële middelen. Van december 2011 tot en met oktober 2015 werden 256
patiënten geïncludeerd, 136 patiënten (53%) werden behandeld met paracetamol.
We vonden geen significant effect van behandeling met paracetamol op de ver-
schuiving van de mRS score (acOR 1.02; 95% CI: 0.7-1.6). Er was geen verschil
in ernstige, ongewenste voorvallen (paracetamol n=35 (26%) versus placebo n=28
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ontwikkelingen in de behandeling van hersenbloedingen.
In hoofdstuk 4 vat ik de belangrijkste bevindingen vanmijn onderzoek beschreven
in dit proefschrift samen en geef ik aanbevelingen voor verder onderzoek. Ik begin
met de bespreking en interpretatie van de resultaten van PAIS 2. Tevens bespreek
ik de verschillende vormen van hypothermie en de resultaten van eerder onder-
zoek. Daarna bediscussieer ik geslacht als prognostische factor bij beroertes.
Ik beschrijf de rol van oestrogenen bij beroerte, geslachtsverschillen in symp-
tomen van beroerte en het gebruik en het effect van behandeling met intraveneuze
alteplase. Ik eindig met de aanbeveling dat het zeer belangrijk is bestaande be-
handelingen voor beroertes te verbeteren en nieuwe therapieën te ontwikkelen,
omdat iedereen op elk moment een beroerte kan krijgen.
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(24%)). We concludeerden dat behandeling met paracetamol veilig is. Het effect
van behandeling met hoge dosering paracetamol op functionele uitkomst na een
doorgemaakte beroerte blijft echter onzeker. Er is een zeer groot onderzoek naar
vroege behandeling met paracetamol na een acute beroerte nodig om een meer
precieze schatting te geven van het behandeleffect.
In hoofdstuk 2.3 onderzoek ik de invloed van baseline lichaamstemperatuur op
het effect van behandeling met alteplase op functionele uitkomst bij patiënten met
een acuut herseninfarct. In in vitro onderzoeken nam de fibrinolytische activiteit
van alteplase per graad Celsius verlaging van de temperatuur af met 5%. Het
effect van lichaamstemperatuur op behandeling met alteplase in patiënten met een
acuut herseninfarct was echter onduidelijk. Ik vond dat het effect van behandeling
met alteplase groter zou kunnen zijn bij hogere lichaamstemperaturen. Bij het
onderzoeken van therapeutische hypothermie na een acute beroerte is het daarom
van belang te controleren voor behandeling met alteplase, en onderzoeken naar
behandeling met alteplase zouden kunnen overwegen lichaamstemperatuur als
potentiele effect modificator te beschouwen.
Hoofdstuk 3 beschrijft geslacht als prognostische factor bij beroertes. Hoofd-
stuk 3.1 bespreekt geslachtsongelijkheid in het krijgen van intraveneuze alteplase
behandeling. We vonden dat vrouwen even vaak worden behandeld met intra-
veneuze alteplase als mannen wanneer ze op tijd voor behandeling in het zieken-
huis aankomen. Echter wanneer we de hele weg, die patiënten met een beroerte
afleggen, onderzoeken, blijkt dat minder vrouwen binnen 4 uur het ziekenhuis
bereiken dan mannen en daarom minder vaak met intraveneuze alteplase worden
behandeld. Dit verschil zou verklaard kunnen worden door de gemiddeld hogere
leeftijd waarop vrouwen een beroerte krijgen, waardoor ze vaker alleenstaand zijn.
Hoofdstuk 3.2 beschrijft geslachtsverschillen in functionele uitkomst na intra-
arteriële behandeling bij een acuut herseninfarct. We toonden in het MR CLEAN
onderzoek aan dat mannen veel baat hadden van intra-arteriële behandeling,
terwijl we bij vrouwen geen gunstig effect vonden van intra-arteriële behandeling.
Deze bevinding heeft geen solide biologische verklaring. Vrouwen leken een
licht ongunstiger profiel te hebben, met als gevolg een hogere mortaliteit en meer
ernstige, ongewenste voorvallen. Statische analyse van alle onderzoeken naar
intra-arteriële behandeling liet inderdaad geen verschil zien tussen mannen en
vrouwen in functionele uitkomst na intra-arteriële behandeling. Deze afwegingen
suggereren dat kans de plausibele verklaring is voor onze bevindingen en maken
duidelijk dat vrouwen intra-arteriële behandeling niet onthouden moet worden.
In hoofdstuk 3.3 onderzoek ik geslachtsverschillen in lange termijn functionele
uitkomst bij patiënten met een spontane hersenbloeding. Voor dit onderzoek
analyseerden we gegevens van 823 patiënten uit een prospectieve ziekenhuis
registratie. We vonden dat vrouwen gemiddeld ouder zijn dan mannen wanneer zij
een hersenbloeding krijgen. Mannen daarentegen hadden vaker hypertensie en
diep gelegen bloedingen. Er waren geen verschillen in lange termijn functionele
uitkomst en mortaliteit tussen mannen en vrouwen. De ongecorrigeerd slechtere
functionele uitkomst bij vrouwen lijkt te kunnen worden verklaard door het leeftijds-
verschil. Mannen en vrouwen lijken dus beiden te gaan profiteren van nieuwe
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Dankwoord
Nu dit proefschrift is afgerond, kan ik terugkijken op een uitdagende en leerzame
onderzoeksperiode. Tijdens deze periode coördineerde ik een nationaal multicen-
ter onderzoek; dit bracht veel sociale contacten zich mee en leerde mij veel over
samenwerking en communicatie. Het was ook een periode van doorzetten, want
het was niet altijd makkelijk om onderzoek doen te combineren met de opleiding tot
neuroloog. Daarbij was de hulp en steun van anderen onmisbaar. Het proefschrift
dat nu voor u ligt, is dan ook het resultaat van samenwerken met vele anderen.
Deze mensen wil ik graag bedanken voor hun inzet. Een aantal van hen wil ik
graag speciaal noemen.
Ten eerste wil ik mijn promotor prof. dr. D.W.J. Dippel bedanken. Beste Diederik,
het schrijven van dit proefschrift was een langdurig proces, dat gepaard ging met
ups en downs, zowel professioneel als persoonlijk. Je gaf me de ruimte toen ik die
nodig had en was er toen ik de motivatie weer terug gevonden had. Je bent een
enthousiaste en prettige neuroloog-opleider en een bevlogen wetenschappelijk
onderzoeker. Van je scherpe blik en vermogen te structureren heb ik veel geleerd.
Hartelijk dank voor de fijne begeleiding en je vlotte reactiesnelheid in de laatste
periode, zonder dat was dit proefschrift niet afgekomen voordat Bente werd ge-
boren. Ik hoop nog veel van je te mogen leren.
Tevens wil ik mijn copromotor dr. H.B. van der Worp bedanken. Beste Bart,
door de afstand was je wat meer op de achtergrond, maar daarmee niet minder
belangrijk. Je hebt oog voor detail en je kritische vragen tijdens ons wekelijkse
PAIS 2 overleg waren onmisbaar, net als je scherpe inhoudelijke en tekstuele
opmerkingen bij manuscripten. Hartelijk dank daarvoor en ik hoop nog veel met je
te mogen samenwerken.
De leden van de kleine promotiecommissie, prof. dr. ir. H. Boersma, prof. dr.
Y.B.W.M. Roos en prof. dr. E.J.G. Sijbrands, dank ik voor het beoordelen van mijn
proefschrift en het plaatsnemen in de commissie. Ik waardeer het erg dat ik met u
van gedachten mag wisselen over mijn proefschrift.
De overige leden van de promotiecommissie, prof. dr. P.J. Koudstaal, prof. dr.
A.H.E.M. Maas en prof. dr. A.G. Vulto, dank ik voor het plaatsnemen in de com-
missie.
Beste Peter, het begon met een keuze-onderzoek naar homocysteïne polymor-
fismen bij herseninfarcten en leidde tot de opleiding tot neuroloog en een pro-
motietraject. Dank voor je aanstekelijke enthousiasme voor het vak neurologie
(bijvoorbeeld de zeer interessante en klinisch relevante bedside teachings) en het
neurovasculaire deelgebied in het bijzonder. Ik hoop nog vaak van je enthousiasme
te mogen genieten.
Beste prof. dr. Maas, ik waardeer het zeer dat ik met u met gedachten mag
wisselen over mijn proefschrift en de invloed van geslacht in de geneeskunde.
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de toekomst vaker met jullie te mogen (samen)werken.
Mijn tijd op de 22e verdieping was niet zo gezellig geweest zonder mijn onder-
zoekscollega’s Bianca, Christine, Danielle, Elise, Femke, Harro, Janne, Janneke,
Julia, Lize, Stephan, Tessel, Tsz, Wan Zheng en wie ik verder nog vergeten ben.
Dank voor de heerlijke taarten die jullie bakten voor het neuro-lekkers op don-
derdag en de gezelligheid.
Een promotieonderzoek is niet compleet zonder congresbezoeken. Ik dank mijn
mede congresgangers (van de neurovasculaire groep) Ladbon, Fop, Renske,
Maaike, Dorien, Bob, Hester, Esmee, Saloua, Marileen, Lisa en Paula voor hun
support wanneer ik een presentatie mocht houden en de gezelligheid buiten de
congresuren om. Beste Maaike, ik mocht je begeleiden tijdens de afronding van je
opleiding tot PA. Van je timemanagement en precisie kunnen velen wat leren en je
oprechte interesse in anderen is hartverwarmend. Hartelijk dank voor je interesse
en steun tijdens mijn onderzoeksperiode. Beste Anouk, we werkten de laatste
maanden samen bij de voorbereiding van het stroke congres en je was me net een
stapje voor met je proefschrift. Hierdoor kon ik veel van je afkijken. Dank voor de
gezellige lunches en wandelingetjes door het Museumpark.
Tweemaal heb ik een periode op de 22e verdieping van de toren gewerkt: in
het begin een jaar fulltime en tijdens de afronding van dit proefschrift één dag per
week. Ik wil mijn kamergenoten van het eerste uur Evita, Puck en Debbie bedanken
voor de vele koppen koffie en vooral thee die we voor elkaar hebben gezet, het
met elkaar van gedachten wisselen over de meest uiteenlopende onderwerpen
en de steun. Beste Debbie, a.k.a. pietje Media. Als er iemand hard werkt, dan
ben jij het wel. Ik waardeer je doorzettingsvermogen en vasthoudendheid, maar
ook je ontwapenende humor. Hoogtepunten waren wel de trappenhuis-scene in
Hamburg, onze zwarte pieten act en de ESO Summer School in Debrecen. Jam-
mer dat je niet in Rotterdam kon blijven. Ik hoop dat je zelf ook snel je proefschrift
afrondt. Mijn kamergenoten van het laatste uur Maxim, Kelly en Jennifer dank
ik voor hun afleiding en gezelligheid tijdens de afronding van mijn proefschrift.
Soms ging ik met tegenzin aan de slag, maar jullie aanwezigheid maakte het werk
een stuk aangenamer en gezelliger. Succes en veel plezier tijdens jullie eigen
onderzoeksperiode.
Working on the neuro-intensive care ward from the University Hospital of Erlangen
has been a special experience and crucial for my further professional and personal
development. I would like to thank professor Stefan Schwab for giving me the
opportunity and my colleagues Natalia, Claudia, Julia, Kosmas, Katrin, Jasmin,
Matthias, Christina, Klemenz, Juliane, Kristin, Marina, Stefan, Tobias, Bastian,
Antje and Vanessa for the warm welcome and cooperation. I would like to address
a special thanks to professor Hagen Huttner and Joji Kuramatsu. Dear Hagen and
Joji, thank you for giving me the opportunity to work with your data on ICH and
write a paper together. I am looking forward to our next project.
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Beste prof. dr. Vulto, hartelijk dank voor de ondersteuning bij de uitvoering van
PAIS 2.
Het belangrijkste gedeelte van dit proefschrift bestaat uit het PAIS 2 onderzoek, een
Nederlands multicenter onderzoek. Dit onderzoek had niet kunnen plaatsvinden
zonder de inzet van vele mensen, die ik hiervoor wil bedanken. Ik wil de leden
van de stuurgroep van PAIS 2, Hester Lingsma, Tobien Schreuder, Annemieke
Ruitenberg, Ritu Saxena, Lisette Maasland, Jordie van Tuijl, Ben Jansen, Renske
Van den Berg-Vos, Frederique Vermeij, Peter Koudstaal, Jaap Kappelle en Ale
Algra bedanken. Het is jammer dat we met elkaar de 1500 patiënten niet hebben
mogen halen, maar het resultaat mag er desondanks zijn. Een speciaal woord van
dank gaat hierbij uit naar Heleen den Hertog. Beste Heleen, als voorganger bij
PAIS en voorbeeld als AIOS en neuroloog ben ik je veel dank verschuldigd. Je
hebt me erg geholpen bij het afronden van het PAIS 2 onderzoek en ik waardeer
je input en ideeën altijd zeer. Jammer dat je, om begrijpelijke reden overigens, niet
in de commissie kunt plaatsnemen. Graag wil ik hier ook Maarten van Gemert
noemen. Beste Maarten, je was al topincludeerder bij PAIS en ook bij PAIS 2 heb
je de meeste patiënten weten te motiveren voor het onderzoek. Je praktische kijk
hield ons met de beide benen op de grond. Hartelijk dank daarvoor.
Ook wil ik iedereen, die voor het PAIS 2 onderzoek patiënten geïncludeerd en
gegevens verzameld heeft, bedanken: neurologen, AIOS, physician assistents, ver-
pleegkundigen en secretaresses van het Meander Medisch Centrum, UMC Utrecht,
Erasmus MC, Zuyderland Medisch Centrum, Medisch Spectrum Twente, Elisabeth
Twee Steden ziekenhuis, Van Weel Bethesda ziekenhuis, OLVG, Maasstad zieken-
huis, Admiraal de Ruyter ziekenhuis en Franciscus Gasthuis.
Een klinisch onderzoek kan niet plaatsvinden zonder de medewerking van patiën-
ten. Ik dank daarom alle patiënten en hun families voor deelname aan het onder-
zoek en het in ons gestelde vertrouwen.
Verder dank ik Lourens van Briemen en Eric Brouwer voor de ICT-ondersteuning.
Naziha el Ghannouti en Esther van der Heijden dank ik voor hun ondersteuning bij
de uitvoering van het PAIS 2 onderzoek. Beste Naziha, je reisde het hele land door
voor het PAIS 2 onderzoek, alleen met de trein of samen in de auto. Daarnaast had
je je handen vol aan het invoeren van data, het bellen van patiënten en opsturen
van flessen wijn en dozen Merci. Zonder jou hadden we het onderzoek al veel
eerder moeten stoppen. Hartelijk dank voor de samenwerking en je gezelligheid.
Alle coauteurs van mijn manuscripten wil ik bedanken voor hun intellectuele bij-
drage.
Mijn collega’s van de afdeling neurologie Erasmus MC dank ik voor de prettige
samenwerking en gezelligheid. In het bijzonder dank ik Robert van den Berg voor
zijn hulp bij en uitleg over LaTeX.
Mijn collega’s van het Franciscus Gasthuis en Elisabeth Twee Steden zieken-
huis wil ik bedanken voor een leerzame tijd en goede samenwerking. Ik hoop in
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mijn hart. Lieve mama, wat had je deze vreugde graag gedeeld met papa, net als
de vreugde die Bente je geeft. Ik heb bewondering voor de veerkracht die je hebt
en de vastberadenheid waarmee je het leven zonder papa opnieuw vormgeeft. Ik
hoop nog vele bijzondere herinneringen met je te mogen maken.
Lieve Willem, waar moet ik beginnen? Als er iemand is zonder wie dit proef-
schrift niet mogelijk was geweest, dan ben jij het. Je kent me door en door en weet
vaak nog eerder dan ikzelf hoe ik me voel. Jouw relativeringsvermogen zet me
weer met beide benen op de grond als ik het even niet meer overzie. Je geeft
me de rust en ruimte me te ontwikkelen en weet het beste in me boven te halen.
Je bent bovendien de beste en meest liefdevolle papa die ik me voor Bente kan
wensen. Je maakt me gelukkig, elke dag weer.
Lieve Bente, dat je werd geboren vlak nadat ik dit proefschrift had afgerond, is wat
mij betreft geen toeval. Je was klaar in mijn buik en klaar voor het leven. Jouw
onvoorwaardelijke liefde is vertederend en jouw brede glimlach aanstekelijk en
verslavend. Je maakt me bewust van wat echt belangrijk is in het leven, namelijk
van elkaar genieten. Het leven met jou is vol avonturen en ik kijk uit naar alle
avonturen die we samen nog gaan meemaken.
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Living in Erlangen would not have been the same without my friends Roland, Eva
and “die kleine Maus” Johanna, Jelena, Julia and Daniela. Dear Roland and Eva,
your unconditional friendship made my start in Erlangen easier and my stay far
more pleasant. I will always remember our grill nights on your balcony, the German
beers we had together and the walks we made with little Johanna. Julia, we share
the love for reading and you introduced me to some awesome German writers.
We went to the movies and you already visited Rotterdam last year. I hope we will
meet again soon. Jelena and Daniela, colleagues became friends since we share
the interest in neuro-intensive care. But you also showed me around in Erlangen
and surroundings and made me feel home. I hope we will keep in touch over time.
Het schrijven van een proefschrift is niet mogelijk zonder ontspanning op z’n
tijd. Ik dank mijn bestuursgenootjes van het 38ste bestuur van de MFVR voor
de gezellige avondjes met meestal net iets te veel wijn. Lieve Floor, ik denk met
veel plezier terug aan onze vrijdagse lunches in de stad en onze saunabezoeken.
In alle ontspanning hadden we openhartige gesprekken die mij menig inzicht in
mezelf hebben gegeven. Gaan we snel weer bubbels drinken en naar de sauna?
Mijn paranimfen, Susanne Fonville en Willemijn Idema, ontzettend leuk en bij-
zonder dat jullie op deze belangrijke dag naast me willen staan. Lieve Suus, a.k.a.
pietje Posterior, met je aanstekelijke lach heb je me door moeilijke momenten heen
geholpen én voor onvergetelijke momenten gezorgd. We groeiden in onze rol
als onderzoeker en arts-assistent tijdens vele congressen, Biemonds en de ESO
Summer School in Debrecen, Hongarije. Daarnaast genoten we van het leven
onder het genot van lekker eten en drinken. Ik waardeer jouw organisatietalent,
optimisme en gezelligheid. Ik hoop je lach nog vaak te mogen horen.
Lieve Wil, sinds we samen in het 38ste bestuur van de MFVR hebben gezeten
zijn we vriendinnen. We kregen tegelijkertijd onze doctoraalbul en je was erbij
toen ik de belofte van Hippocrates aflegde. Nu sta je naast me op deze bijzondere
dag. Je bent er altijd voor me, tijdens moeilijke én mooie momenten. Je bent zeer
sociaal en oprecht en weet de juiste vragen te stellen om me aan het denken te
zetten. Samen kunnen we ook erg van het leven genieten. Zo kijk ik met plezier op
onze gezamenlijke vakanties met giechelwijn en oesters. Wat wordt onze volgende
bestemming?
Lieve schoonfamilie, Arie en Margot, Wieke en Tom, en Frederike, dank voor
jullie interesse, steun, afleiding, en, in de laatste periode, zorg voor Bente wanneer
ik weer eens druk was met de afronding van dit proefschrift en de voorbereiding
op de verdediging. Fijn dat jullie er altijd voor ons zijn.
Lieve mama en papa in herinnering, zonder jullie was ik niet gekomen waar ik nu
sta. Van jongs af aan hebben jullie me de vrijheid gegeven de wereld te ontdekken,
mezelf te ontwikkelen en steeds maar verder te leren en te studeren. Lieve papa,
het doet me veel verdriet dat je deze dag niet mee kan maken, want ik weet hoe
trots je geweest zou zijn. Maar weet dat je er altijd bij bent, in mijn gedachten en in
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Anyone can suffer a stroke at any time and the consequences of 
stroke are often severe. It therefore remains an important chal-
lenge to find new prognostic factors and to further evaluate the 
importance of known prognostic factors, as this may improve clini-
cal knowledge and management, and may guide new therapies. 
This thesis focusses on the influence of the prognostic factors tem-
perature and sex on treatment and outcome of patients with acute 
stroke. We aimed to assess the effect of body temperature manage-
ment on functional outcome in patients with acute stroke by per-
forming the Paracetamol (Acetaminophen) in Stroke 2 (PAIS 2) trial. 
In addition, we investig ted sex differences in the acute manage-
ment of ischemic stroke and sex differences in long-term functional 
outcome after intracerebral hemorrhage.   
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